þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Incorporated in New Jersey | I.R.S. Employer | |
Identification No. 22-1918501 |
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Sales |
$ | 12,151 | $ | 11,346 | $ | 23,732 | $ | 22,768 | ||||||||
Costs, Expenses and Other |
||||||||||||||||
Materials and production |
4,284 | 4,549 | 8,343 | 9,764 | ||||||||||||
Marketing and administrative |
3,525 | 3,175 | 6,689 | 6,397 | ||||||||||||
Research and development |
1,936 | 2,179 | 4,094 | 4,230 | ||||||||||||
Restructuring costs |
668 | 526 | 654 | 814 | ||||||||||||
Equity income from affiliates |
(55 | ) | (43 | ) | (193 | ) | (180 | ) | ||||||||
Other (income) expense, net |
121 | (281 | ) | 744 | (113 | ) | ||||||||||
10,479 | 10,105 | 20,331 | 20,912 | |||||||||||||
Income Before Taxes |
1,672 | 1,241 | 3,401 | 1,856 | ||||||||||||
Taxes on Income |
(382 | ) | 461 | 276 | 746 | |||||||||||
Net Income |
$ | 2,054 | $ | 780 | $ | 3,125 | $ | 1,110 | ||||||||
Less: Net Income Attributable to Noncontrolling Interests |
30 | 28 | 58 | 59 | ||||||||||||
Net Income Attributable to Merck & Co., Inc. |
$ | 2,024 | $ | 752 | $ | 3,067 | $ | 1,051 | ||||||||
Basic Earnings per Common Share Attributable to
Merck & Co., Inc. Common Shareholders |
$ | 0.65 | $ | 0.24 | $ | 0.99 | $ | 0.34 | ||||||||
Earnings per Common Share Assuming Dilution Attributable
to Merck & Co., Inc. Common Shareholders |
$ | 0.65 | $ | 0.24 | $ | 0.98 | $ | 0.33 | ||||||||
Dividends Declared per Common Share |
$ | 0.38 | $ | 0.38 | $ | 0.76 | $ | 0.76 | ||||||||
- 2 -
June 30, | December 31, | |||||||
2011 | 2010 | |||||||
Assets |
||||||||
Current Assets |
||||||||
Cash and cash equivalents |
$ | 12,342 | $ | 10,900 | ||||
Short-term investments |
1,639 | 1,301 | ||||||
Accounts receivable (net of allowance for doubtful accounts of $128
in 2011 and $104 in 2010) |
8,475 | 7,344 | ||||||
Inventories (excludes inventories of $1,408 in 2011 and $1,194
in 2010 classified in Other assets see Note 6) |
6,225 | 5,868 | ||||||
Deferred income taxes and other current assets |
3,687 | 3,651 | ||||||
Total current assets |
32,368 | 29,064 | ||||||
Investments |
2,175 | 2,175 | ||||||
Property,
Plant and Equipment, at cost, net of accumulated depreciation
of $15,195 in 2011 and $13,481 in 2010 |
16,671 | 17,082 | ||||||
Goodwill |
12,382 | 12,378 | ||||||
Other Intangibles, Net |
37,065 | 39,456 | ||||||
Other Assets |
5,534 | 5,626 | ||||||
$ | 106,195 | $ | 105,781 | |||||
Liabilities and Equity |
||||||||
Current Liabilities |
||||||||
Loans payable and current portion of long-term debt |
$ | 2,523 | $ | 2,400 | ||||
Trade accounts payable |
2,143 | 2,308 | ||||||
Accrued and other current liabilities |
8,747 | 8,514 | ||||||
Income taxes payable |
1,174 | 1,243 | ||||||
Dividends payable |
1,176 | 1,176 | ||||||
Total current liabilities |
15,763 | 15,641 | ||||||
Long-Term Debt |
15,783 | 15,482 | ||||||
Deferred Income Taxes and Noncurrent Liabilities |
16,727 | 17,853 | ||||||
Merck & Co., Inc. Stockholders Equity |
||||||||
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,576,948,356 shares in 2011 and 2010 |
1,788 | 1,788 | ||||||
Other paid-in capital |
40,657 | 40,701 | ||||||
Retained earnings |
38,243 | 37,536 | ||||||
Accumulated other comprehensive loss |
(2,776 | ) | (3,216 | ) | ||||
77,912 | 76,809 | |||||||
Less treasury stock, at cost
493,935,906 shares in 2011 and 494,841,533 shares in 2010 |
22,416 | 22,433 | ||||||
Total Merck & Co., Inc. stockholders equity |
55,496 | 54,376 | ||||||
Noncontrolling Interests |
2,426 | 2,429 | ||||||
Total equity |
57,922 | 56,805 | ||||||
$ | 106,195 | $ | 105,781 | |||||
- 3 -
Six Months Ended | ||||||||
June 30, | ||||||||
2011 | 2010 | |||||||
Cash Flows from Operating Activities |
||||||||
Net income |
$ | 3,125 | $ | 1,110 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
3,663 | 3,635 | ||||||
Intangible asset impairment charges |
439 | 27 | ||||||
Equity income from affiliates |
(193 | ) | (180 | ) | ||||
Dividends and distributions from equity affiliates |
121 | 182 | ||||||
Gain on AstraZeneca asset option exercise |
| (443 | ) | |||||
Deferred income taxes |
(841 | ) | (319 | ) | ||||
Share-based compensation |
200 | 274 | ||||||
Other |
(456 | ) | 410 | |||||
Net changes in assets and liabilities |
(1,485 | ) | (5 | ) | ||||
Net Cash Provided by Operating Activities |
4,573 | 4,691 | ||||||
Cash Flows from Investing Activities |
||||||||
Capital expenditures |
(689 | ) | (680 | ) | ||||
Purchases of securities and other investments |
(3,066 | ) | (4,235 | ) | ||||
Proceeds from sales of securities and other investments |
2,890 | 1,700 | ||||||
Dispositions of businesses, net of cash divested |
323 | | ||||||
Acquisitions of businesses, net of cash acquired |
(373 | ) | (141 | ) | ||||
Proceeds from AstraZeneca option exercise |
| 647 | ||||||
Other |
(28 | ) | 25 | |||||
Net Cash Used in Investing Activities |
(943 | ) | (2,684 | ) | ||||
Cash Flows from Financing Activities |
||||||||
Net change in short-term borrowings |
1,396 | 1,658 | ||||||
Payments on debt |
(1,265 | ) | (626 | ) | ||||
Purchases of treasury stock |
(314 | ) | (1,297 | ) | ||||
Dividends paid to stockholders |
(2,351 | ) | (2,378 | ) | ||||
Proceeds from exercise of stock options |
162 | 237 | ||||||
Other |
(57 | ) | (115 | ) | ||||
Net Cash Used in Financing Activities |
(2,429 | ) | (2,521 | ) | ||||
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
241 | (131 | ) | |||||
Net Increase (Decrease) in Cash and Cash Equivalents |
1,442 | (645 | ) | |||||
Cash and Cash Equivalents at Beginning of Year |
10,900 | 9,311 | ||||||
Cash and Cash Equivalents at End of Period |
$ | 12,342 | $ | 8,666 | ||||
- 4 -
- 5 -
- 6 -
Three Months Ended June 30, 2011 | Six Months Ended June 30, 2011 | |||||||||||||||||||||||||||||||
Separation | Accelerated | Separation | Accelerated | |||||||||||||||||||||||||||||
($ in millions) | Costs | Depreciation | Other | Total | Costs | Depreciation | Other | Total | ||||||||||||||||||||||||
Merger Restructuring Program |
||||||||||||||||||||||||||||||||
Materials and production |
$ | | $ | 91 | $ | 5 | $ | 96 | $ | | $ | 152 | $ | 5 | $ | 157 | ||||||||||||||||
Marketing and administrative |
| 22 | 1 | 23 | | 45 | 1 | 46 | ||||||||||||||||||||||||
Research and development |
| 38 | (22 | ) | 16 | | 80 | (19 | ) | 61 | ||||||||||||||||||||||
Restructuring costs |
646 | | 27 | 673 | 607 | | 50 | 657 | ||||||||||||||||||||||||
646 | 151 | 11 | 808 | 607 | 277 | 37 | 921 | |||||||||||||||||||||||||
2008 Restructuring Program |
||||||||||||||||||||||||||||||||
Materials and production |
| 4 | 2 | 6 | | 6 | 2 | 8 | ||||||||||||||||||||||||
Restructuring costs |
(7 | ) | | 2 | (5 | ) | (8 | ) | | 5 | (3 | ) | ||||||||||||||||||||
(7 | ) | 4 | 4 | 1 | (8 | ) | 6 | 7 | 5 | |||||||||||||||||||||||
$ | 639 | $ | 155 | $ | 15 | $ | 809 | $ | 599 | $ | 283 | $ | 44 | $ | 926 | |||||||||||||||||
Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 | |||||||||||||||||||||||||||||||
Separation | Accelerated | Separation | Accelerated | |||||||||||||||||||||||||||||
($ in millions) | Costs | Depreciation | Other | Total | Costs | Depreciation | Other | Total | ||||||||||||||||||||||||
Merger Restructuring Program |
||||||||||||||||||||||||||||||||
Materials and production |
$ | | $ | 149 | $ | 22 | $ | 171 | $ | | $ | 174 | $ | 22 | $ | 196 | ||||||||||||||||
Research and development |
| 113 | 31 | 144 | | 113 | 37 | 150 | ||||||||||||||||||||||||
Restructuring costs |
374 | 41 | 100 | 515 | 583 | 41 | 143 | 767 | ||||||||||||||||||||||||
374 | 303 | 153 | 830 | 583 | 328 | 202 | 1,113 | |||||||||||||||||||||||||
2008 Restructuring Program |
||||||||||||||||||||||||||||||||
Materials and production |
| 11 | 36 | 47 | | 40 | 36 | 76 | ||||||||||||||||||||||||
Restructuring costs |
12 | | 7 | 19 | 31 | | 24 | 55 | ||||||||||||||||||||||||
12 | 11 | 43 | 66 | 31 | 40 | 60 | 131 | |||||||||||||||||||||||||
$ | 386 | $ | 314 | $ | 196 | $ | 896 | $ | 614 | $ | 368 | $ | 262 | $ | 1,244 | |||||||||||||||||
- 7 -
Separation | Accelerated | |||||||||||||||
($ in millions) | Costs | Depreciation | Other | Total | ||||||||||||
Merger Restructuring Program |
||||||||||||||||
Restructuring reserves January 1, 2011 |
$ | 859 | $ | | $ | 64 | $ | 923 | ||||||||
Expense |
607 | 277 | 37 | 921 | ||||||||||||
(Payments) receipts, net |
(257 | ) | | (71 | ) | (328 | ) | |||||||||
Non-cash activity |
| (277 | ) | 16 | (261 | ) | ||||||||||
Restructuring reserves June 30, 2011 (1) |
$ | 1,209 | $ | | $ | 46 | $ | 1,255 | ||||||||
2008 Restructuring Program |
||||||||||||||||
Restructuring reserves January 1, 2011 |
$ | 196 | $ | | $ | | $ | 196 | ||||||||
Expense |
(8 | ) | 6 | 7 | 5 | |||||||||||
(Payments) receipts, net |
(13 | ) | | (2 | ) | (15 | ) | |||||||||
Non-cash activity |
| (6 | ) | (5 | ) | (11 | ) | |||||||||
Restructuring reserves June 30, 2011 (1) |
$ | 175 | $ | | $ | | $ | 175 | ||||||||
(1) | The cash outlays
associated with the Merger Restructuring Program and the 2008
Restructuring Program are expected
to be substantially completed by the end of 2013 and 2011,
respectively, with the exception of certain
actions, principally manufacturing-related, which are expected to be completed by 2015. |
- 8 -
- 9 -
- 10 -
- 11 -
June 30, 2011 | December 31, 2010 | |||||||||||||||||||||||||
Fair Value of Derivative | U.S. Dollar | Fair Value of Derivative | U.S. Dollar | |||||||||||||||||||||||
($ in millions) | Balance Sheet Caption | Asset | Liability | Notional | Asset | Liability | Notional | |||||||||||||||||||
Derivatives Designated as Hedging Instruments |
||||||||||||||||||||||||||
Foreign exchange contracts (current) |
Deferred income taxes and other current assets |
$ | 91 | $ | | $ | 3,696 | $ | 167 | $ | | $ | 2,344 | |||||||||||||
Foreign exchange contracts (non-current) |
Other assets | 288 | | 4,469 | 310 | | 3,720 | |||||||||||||||||||
Foreign exchange contracts (current) |
Accrued and other current liabilities |
| 40 | 1,825 | | 18 | 1,505 | |||||||||||||||||||
Foreign exchange contracts (non-current) |
Deferred income taxes and noncurrent liabilities |
| 3 | 113 | | 6 | 503 | |||||||||||||||||||
Interest rate swaps (current) |
Deferred income taxes and other current assets |
6 | | 250 | | | | |||||||||||||||||||
Interest rate swaps (non-current) |
Other assets | 66 | | 1,600 | 56 | | 1,000 | |||||||||||||||||||
Interest rate swaps (non-current) |
Deferred income taxes and noncurrent liabilities |
| | | | 7 | 850 | |||||||||||||||||||
$ | 451 | $ | 43 | $ | 11,953 | $ | 533 | $ | 31 | $ | 9,922 | |||||||||||||||
Derivatives Not Designated as Hedging Instruments |
||||||||||||||||||||||||||
Foreign exchange contracts (current) |
Deferred income taxes and other current assets |
$ | 106 | $ | | $ | 7,894 | $ | 95 | $ | | $ | 6,295 | |||||||||||||
Foreign exchange contracts (current) |
Accrued and other current liabilities |
| 25 | 3,736 | | 30 | 4,229 | |||||||||||||||||||
$ | 106 | $ | 25 | $ | 11,630 | $ | 95 | $ | 30 | $ | 10,524 | |||||||||||||||
$ | 557 | $ | 68 | $ | 23,583 | $ | 628 | $ | 61 | $ | 20,446 | |||||||||||||||
- 12 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Derivatives designated in fair value hedging relationships |
||||||||||||||||
Interest rate swap contracts |
||||||||||||||||
Amount of
gain recognized in Other (income)
expense, net on derivatives |
$ | (126 | ) | $ | (13 | ) | $ | (163 | ) | $ | (35 | ) | ||||
Amount of loss recognized in Other (income)
expense, net on hedged item |
126 | 13 | 163 | 35 | ||||||||||||
Derivatives designated in foreign currency cash flow hedging relationships |
||||||||||||||||
Foreign exchange contracts |
||||||||||||||||
Amount of loss (gain) reclassified from AOCI to Sales |
20 | (5 | ) | 27 | 14 | |||||||||||
Amount of loss (gain) recognized in OCI on derivatives |
69 | (190 | ) | 252 | (284 | ) | ||||||||||
Derivatives designated in foreign currency net investment hedging relationships |
||||||||||||||||
Foreign exchange contracts |
||||||||||||||||
Amount of gain recognized in Other (income) expense,
net on derivatives (1) |
(2 | ) | | (8 | ) | | ||||||||||
Amount of loss recognized in OCI on derivatives |
33 | | 34 | | ||||||||||||
Derivatives not designated in a hedging relationship |
||||||||||||||||
Foreign exchange contracts |
||||||||||||||||
Amount of loss (gain) recognized in Other (income)
expense, net on derivatives (2) |
33 | (117 | ) | 349 | (185 | ) | ||||||||||
Amount of gain recognized in Sales on hedged item |
| (46 | ) | | (113 | ) | ||||||||||
(1) | There was no ineffectiveness on the hedge. Represents the amount excluded
from hedge effectiveness testing. |
|
(2) | These derivative contracts mitigate changes in the value of remeasured foreign
currency denominated monetary assets and liabilities attributable to changes in foreign
currency exchange rates. |
- 13 -
Fair Value Measurements Using | Fair Value Measurements Using | |||||||||||||||||||||||||||||||
Quoted Prices | Significant | Quoted Prices | Significant | |||||||||||||||||||||||||||||
In Active | Other | Significant | In Active | Other | Significant | |||||||||||||||||||||||||||
Markets for | Observable | Unobservable | Markets for | Observable | Unobservable | |||||||||||||||||||||||||||
Identical Assets | Inputs | Inputs | Identical Assets | Inputs | Inputs | |||||||||||||||||||||||||||
(Level 1) | (Level 2) | (Level 3) | Total | (Level 1) | (Level 2) | (Level 3) | Total | |||||||||||||||||||||||||
($ in millions) | June 30, 2011 | December 31, 2010 | ||||||||||||||||||||||||||||||
Assets |
||||||||||||||||||||||||||||||||
Investments |
||||||||||||||||||||||||||||||||
Commercial paper |
$ | | $ | 1,411 | $ | | $ | 1,411 | $ | | $ | 1,046 | $ | | $ | 1,046 | ||||||||||||||||
Corporate notes and bonds |
| 1,377 | | 1,377 | | 1,133 | | 1,133 | ||||||||||||||||||||||||
U.S. government and
agency securities |
| 523 | | 523 | | 500 | | 500 | ||||||||||||||||||||||||
Municipal securities |
| | | | | 361 | | 361 | ||||||||||||||||||||||||
Asset-backed securities (1) |
| 183 | | 183 | | 171 | | 171 | ||||||||||||||||||||||||
Mortgage-backed securities
(1) |
| 134 | | 134 | | 99 | 13 | 112 | ||||||||||||||||||||||||
Foreign government bonds |
| 56 | | 56 | | 10 | | 10 | ||||||||||||||||||||||||
Equity securities |
96 | 31 | | 127 | 117 | 23 | | 140 | ||||||||||||||||||||||||
Other debt securities |
| 3 | | 3 | | 3 | | 3 | ||||||||||||||||||||||||
96 | 3,718 | | 3,814 | 117 | 3,346 | 13 | 3,476 | |||||||||||||||||||||||||
Other assets |
||||||||||||||||||||||||||||||||
Securities held for employee
compensation |
197 | | | 197 | 181 | | | 181 | ||||||||||||||||||||||||
Derivative assets (2) |
||||||||||||||||||||||||||||||||
Purchased currency options |
| 379 | | 379 | | 477 | | 477 | ||||||||||||||||||||||||
Forward exchange contracts |
| 106 | | 106 | | 95 | | 95 | ||||||||||||||||||||||||
Interest rate swaps |
| 72 | | 72 | | 56 | | 56 | ||||||||||||||||||||||||
| 557 | | 557 | | 628 | | 628 | |||||||||||||||||||||||||
Total assets |
$ | 293 | $ | 4,275 | $ | | $ | 4,568 | $ | 298 | $ | 3,974 | $ | 13 | $ | 4,285 | ||||||||||||||||
Liabilities |
||||||||||||||||||||||||||||||||
Derivative liabilities (2) |
||||||||||||||||||||||||||||||||
Written currency options |
$ | | $ | 6 | $ | | $ | 6 | $ | | $ | | $ | | $ | | ||||||||||||||||
Forward exchange contracts |
| 62 | | 62 | | 54 | | 54 | ||||||||||||||||||||||||
Interest rate swaps |
| | | | | 7 | | 7 | ||||||||||||||||||||||||
Total liabilities |
$ | | $ | 68 | $ | | $ | 68 | $ | | $ | 61 | $ | | $ | 61 | ||||||||||||||||
(1) | Substantially all of the asset-backed securities are highly-rated (Standard & Poors
rating of AAA and Moodys Investors Service rating of Aaa), secured primarily by credit card,
auto loan, and home equity receivables, with weighted-average lives of primarily 5 years or
less. Mortgage-backed securities represent AAA-rated securities issued or unconditionally
guaranteed as to payment of principal and interest by U.S. government agencies. |
|
(2) | The fair value determination of derivatives includes an assessment of the credit
risk of counterparties to the derivatives and the Companys own credit risk, the effects of
which were not significant. |
- 14 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Beginning balance |
$ | | $ | 20 | $ | 13 | $ | 72 | ||||||||
Sales |
| (8 | ) | (13 | ) | (61 | ) | |||||||||
Settlements |
| | | (2 | ) | |||||||||||
Total realized and unrealized gains (losses) |
||||||||||||||||
Included in: |
||||||||||||||||
Earnings (1) |
| 6 | | 18 | ||||||||||||
Comprehensive income |
| (1 | ) | | (10 | ) | ||||||||||
Ending balance |
$ | | $ | 17 | $ | | $ | 17 | ||||||||
Losses recorded in earnings for Level 3
assets still held at June 30 |
$ | | $ | | $ | | $ | | ||||||||
(1) | Amounts are recorded in Other (income) expense, net. |
June 30, 2011 | December 31, 2010 | ||||||||||||||||||||||||||||||||
Fair | Amortized | Gross Unrealized | Fair | Amortized | Gross Unrealized | ||||||||||||||||||||||||||||
($ in millions) | Value | Cost | Gains | Losses | Value | Cost | Gains | Losses | |||||||||||||||||||||||||
Commercial paper |
$ | 1,411 | $ | 1,411 | $ | | $ | | $ | 1,046 | $ | 1,046 | $ | | $ | | |||||||||||||||||
Corporate notes and bonds |
1,377 | 1,363 | 15 | (1 | ) | 1,133 | 1,124 | 12 | (3 | ) | |||||||||||||||||||||||
U.S. government and agency
securities |
523 | 523 | 2 | (2 | ) | 500 | 501 | 1 | (2 | ) | |||||||||||||||||||||||
Municipal securities |
| | | | 361 | 359 | 4 | (2 | ) | ||||||||||||||||||||||||
Asset-backed securities |
183 | 182 | 1 | | 171 | 170 | 1 | | |||||||||||||||||||||||||
Mortgage-backed securities |
134 | 134 | 1 | (1 | ) | 112 | 108 | 5 | (1 | ) | |||||||||||||||||||||||
Foreign government bonds |
56 | 56 | | | 10 | 10 | | | |||||||||||||||||||||||||
Other debt securities |
3 | 1 | 2 | | 3 | 1 | 2 | | |||||||||||||||||||||||||
Equity securities |
324 | 307 | 17 | | 321 | 295 | 34 | (8 | ) | ||||||||||||||||||||||||
$ | 4,011 | $ | 3,977 | $ | 38 | $ | (4 | ) | $ | 3,657 | $ | 3,614 | $ | 59 | $ | (16 | ) | ||||||||||||||||
- 15 -
June 30, | December 31, | |||||||
($ in millions) | 2011 | 2010 | ||||||
Finished goods |
$ | 1,440 | $ | 1,484 | ||||
Raw materials and work in process |
6,036 | 5,449 | ||||||
Supplies |
298 | 315 | ||||||
Total (approximates current cost) |
7,774 | 7,248 | ||||||
Reduction to LIFO costs |
(141 | ) | (186 | ) | ||||
$ | 7,633 | $ | 7,062 | |||||
Recognized as: |
||||||||
Inventories |
$ | 6,225 | $ | 5,868 | ||||
Other assets |
1,408 | 1,194 | ||||||
- 16 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
AstraZeneca LP |
$ | 44 | $ | 40 | $ | 177 | $ | 165 | ||||||||
Other (1) |
11 | 3 | 16 | 15 | ||||||||||||
$ | 55 | $ | 43 | $ | 193 | $ | 180 | |||||||||
(1) | Primarily reflects results from Sanofi Pasteur MSD and Johnson & Johnson°Merck
Consumer Pharmaceuticals Company. |
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Sales |
$ | 1,181 | $ | 1,297 | $ | 2,336 | $ | 2,590 | ||||||||
Materials and production costs |
516 | 626 | 1,061 | 1,259 | ||||||||||||
Other expense, net |
345 | 313 | 646 | 455 | ||||||||||||
Income before taxes (1) |
$ | 320 | $ | 358 | $ | 629 | $ | 876 | ||||||||
(1) | Mercks partnership returns from AZLP are generally contractually determined and
are not based on a percentage of income from AZLP, other than with respect to the 1% limited
partnership interest discussed above. |
- 17 -
- 18 -
- 19 -
- 20 -
- 21 -
- 22 -
- 23 -
- 24 -
- 25 -
- 26 -
- 27 -
Accumulated | ||||||||||||||||||||||||||||||||||||
Other | Other | Non- | ||||||||||||||||||||||||||||||||||
Common Stock | Paid-In | Retained | Comprehensive | Treasury Stock | Controlling | |||||||||||||||||||||||||||||||
($ in millions) | Shares | Par Value | Capital | Earnings | Loss | Shares | Cost | Interests | Total | |||||||||||||||||||||||||||
Balance January 1, 2010 |
3,563 | $ | 1,781 | $ | 39,683 | $ | 41,405 | $ | (2,767 | ) | 454 | $ | (21,044 | ) | $ | 2,427 | $ | 61,485 | ||||||||||||||||||
Net income attributable to
Merck & Co., Inc. |
| | | 1,051 | | | | | 1,051 | |||||||||||||||||||||||||||
Cash dividends declared on
common stock |
| | | (2,374 | ) | | | | | (2,374 | ) | |||||||||||||||||||||||||
Treasury stock shares purchased |
| | | | | 38 | (1,297 | ) | | (1,297 | ) | |||||||||||||||||||||||||
Share-based compensation
plans and other |
10 | 5 | 655 | | | | 25 | | 685 | |||||||||||||||||||||||||||
Other comprehensive loss |
| | | | (1,892 | ) | | | | (1,892 | ) | |||||||||||||||||||||||||
Net income attributable to
noncontrolling interests |
| | | | | | | 59 | 59 | |||||||||||||||||||||||||||
Distributions attributable to
noncontrolling interests |
| | | | | | | (60 | ) | (60 | ) | |||||||||||||||||||||||||
Balance June 30, 2010 |
3,573 | $ | 1,786 | $ | 40,338 | $ | 40,082 | $ | (4,659 | ) | 492 | $ | (22,316 | ) | $ | 2,426 | $ | 57,657 | ||||||||||||||||||
Balance January 1, 2011 |
3,577 | $ | 1,788 | $ | 40,701 | $ | 37,536 | $ | (3,216 | ) | 495 | $ | (22,433 | ) | $ | 2,429 | $ | 56,805 | ||||||||||||||||||
Net income attributable to
Merck & Co., Inc. |
| | | 3,067 | | | | | 3,067 | |||||||||||||||||||||||||||
Cash dividends declared on
common stock |
| | | (2,360 | ) | | | | | (2,360 | ) | |||||||||||||||||||||||||
Treasury stock shares purchased |
| | | | | 9 | (314 | ) | | (314 | ) | |||||||||||||||||||||||||
Share-based compensation
plans and other |
| | (44 | ) | | | (10 | ) | 331 | | 287 | |||||||||||||||||||||||||
Other comprehensive income |
| | | | 440 | | | | 440 | |||||||||||||||||||||||||||
Net income attributable to
noncontrolling interests |
| | | | | | | 58 | 58 | |||||||||||||||||||||||||||
Distributions attributable to
noncontrolling interests |
| | | | | | | (61 | ) | (61 | ) | |||||||||||||||||||||||||
Balance June 30, 2011 |
3,577 | $ | 1,788 | $ | 40,657 | $ | 38,243 | $ | (2,776 | ) | 494 | $ | (22,416 | ) | $ | 2,426 | $ | 57,922 | ||||||||||||||||||
Accumulated | ||||||||||||||||||||
Employee | Cumulative | Other | ||||||||||||||||||
Benefit | Translation | Comprehensive | ||||||||||||||||||
($ in millions) | Derivatives | Investments | Plans | Adjustment | Income (Loss) | |||||||||||||||
Balance January 1, 2010 |
$ | (42 | ) | $ | 33 | $ | (2,469 | ) | $ | (289 | ) | $ | (2,767 | ) | ||||||
Other comprehensive income (loss) |
179 | (4 | ) | 121 | (2,188 | ) | (1,892 | ) | ||||||||||||
Balance at June 30, 2010 |
$ | 137 | $ | 29 | $ | (2,348 | ) | $ | (2,477 | ) | $ | (4,659 | ) | |||||||
Balance January 1, 2011 |
$ | 41 | $ | 31 | $ | (2,043 | ) | $ | (1,245 | ) | $ | (3,216 | ) | |||||||
Other comprehensive income (loss) |
(137 | ) | (5 | ) | 28 | 554 | 440 | |||||||||||||
Balance at June 30, 2011 |
$ | (96 | ) | $ | 26 | $ | (2,015 | ) | $ | (691 | ) | $ | (2,776 | ) | ||||||
- 28 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Pretax share-based compensation expense |
$ | 107 | $ | 142 | $ | 200 | $ | 274 | ||||||||
Income tax benefit |
(37 | ) | (49 | ) | (69 | ) | (93 | ) | ||||||||
Total share-based compensation expense, net of taxes |
$ | 70 | $ | 93 | $ | 131 | $ | 181 | ||||||||
Six Months Ended | ||||||||
June 30, | ||||||||
2011 | 2010 | |||||||
Expected dividend yield |
4.3 | % | 4.1 | % | ||||
Risk-free interest rate |
2.6 | % | 2.8 | % | ||||
Expected volatility |
23.2 | % | 33.8 | % | ||||
Expected life (years) |
7.0 | 6.8 | ||||||
- 29 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Service cost |
$ | 151 | $ | 147 | $ | 303 | $ | 301 | ||||||||
Interest cost |
180 | 172 | 359 | 349 | ||||||||||||
Expected return on plan assets |
(242 | ) | (215 | ) | (485 | ) | (432 | ) | ||||||||
Net amortization |
46 | 43 | 91 | 88 | ||||||||||||
Termination benefits |
7 | 9 | 17 | 28 | ||||||||||||
Curtailments |
(6 | ) | (1 | ) | (10 | ) | (37 | ) | ||||||||
Settlements |
| (6 | ) | (1 | ) | (7 | ) | |||||||||
$ | 136 | $ | 149 | $ | 274 | $ | 290 | |||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Service cost |
$ | 28 | $ | 28 | $ | 56 | $ | 54 | ||||||||
Interest cost |
35 | 36 | 71 | 74 | ||||||||||||
Expected return on plan assets |
(36 | ) | (33 | ) | (71 | ) | (65 | ) | ||||||||
Net amortization |
(6 | ) | 2 | (9 | ) | 4 | ||||||||||
Termination benefits |
4 | 7 | 6 | 27 | ||||||||||||
Curtailments |
| (2 | ) | 1 | (2 | ) | ||||||||||
$ | 25 | $ | 38 | $ | 54 | $ | 92 | |||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Interest income |
$ | (51 | ) | $ | (22 | ) | $ | (92 | ) | $ | (34 | ) | ||||
Interest expense |
182 | 185 | 368 | 366 | ||||||||||||
Exchange losses |
1 | (4 | ) | 43 | 76 | |||||||||||
Other, net |
(11 | ) | (440 | ) | 425 | (521 | ) | |||||||||
$ | 121 | $ | (281 | ) | $ | 744 | $ | (113 | ) | |||||||
- 30 -
- 31 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Basic Earnings per Common Share |
||||||||||||||||
Net income attributable to Merck & Co., Inc.
common shareholders |
$ | 2,024 | $ | 752 | $ | 3,067 | $ | 1,051 | ||||||||
Less: Income allocated to participating securities |
4 | 3 | 8 | 4 | ||||||||||||
Net income allocated to common shareholders |
$ | 2,020 | $ | 749 | $ | 3,059 | $ | 1,047 | ||||||||
Average common shares outstanding |
3,086 | 3,105 | 3,085 | 3,109 | ||||||||||||
$ | 0.65 | $ | 0.24 | $ | 0.99 | $ | 0.34 | |||||||||
Earnings per Common Share Assuming Dilution |
||||||||||||||||
Net income attributable to Merck & Co., Inc.
common shareholders |
$ | 2,024 | $ | 752 | $ | 3,067 | $ | 1,051 | ||||||||
Less: Income allocated to participating securities |
4 | 3 | 8 | 4 | ||||||||||||
Net income allocated to common shareholders |
$ | 2,020 | $ | 749 | $ | 3,059 | $ | 1,047 | ||||||||
Average common shares outstanding |
3,086 | 3,105 | 3,085 | 3,109 | ||||||||||||
Common shares issuable (1) |
24 | 20 | 21 | 23 | ||||||||||||
Average common shares outstanding assuming dilution |
3,110 | 3,125 | 3,106 | 3,132 | ||||||||||||
$ | 0.65 | $ | 0.24 | $ | 0.98 | $ | 0.33 | |||||||||
(1) | Issuable primarily under share-based compensation plans. |
- 32 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Segment revenues: |
||||||||||||||||
Pharmaceutical segment |
$ | 10,360 | $ | 9,638 | $ | 20,179 | $ | 19,303 | ||||||||
All other segment revenues |
1,665 | 1,525 | 3,275 | 3,095 | ||||||||||||
$ | 12,025 | $ | 11,163 | $ | 23,454 | $ | 22,398 | |||||||||
Segment profits: |
||||||||||||||||
Pharmaceutical segment |
$ | 6,443 | $ | 5,987 | $ | 12,659 | $ | 11,727 | ||||||||
All other segment profits |
655 | 627 | 1,371 | 1,347 | ||||||||||||
$ | 7,098 | $ | 6,614 | $ | 14,030 | $ | 13,074 | |||||||||
- 33 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Pharmaceutical: |
||||||||||||||||
Cardiovascular |
||||||||||||||||
Zetia |
$ | 592 | $ | 564 | $ | 1,174 | $ | 1,098 | ||||||||
Vytorin |
459 | 490 | 939 | 967 | ||||||||||||
Integrilin |
56 | 70 | 120 | 140 | ||||||||||||
Diabetes and Obesity |
||||||||||||||||
Januvia |
779 | 600 | 1,518 | 1,111 | ||||||||||||
Janumet |
321 | 218 | 626 | 419 | ||||||||||||
Diversified Brands |
||||||||||||||||
Cozaar/Hyzaar |
406 | 485 | 832 | 1,267 | ||||||||||||
Zocor |
107 | 117 | 234 | 233 | ||||||||||||
Propecia |
112 | 113 | 218 | 213 | ||||||||||||
Claritin Rx |
65 | 58 | 186 | 157 | ||||||||||||
Remeron |
57 | 59 | 117 | 110 | ||||||||||||
Vasotec/Vaseretic |
59 | 63 | 116 | 122 | ||||||||||||
Proscar |
53 | 56 | 113 | 114 | ||||||||||||
Infectious Disease |
||||||||||||||||
Isentress |
337 | 267 | 629 | 499 | ||||||||||||
Cancidas |
168 | 150 | 326 | 303 | ||||||||||||
PegIntron |
154 | 185 | 319 | 371 | ||||||||||||
Primaxin |
136 | 158 | 272 | 317 | ||||||||||||
Invanz |
103 | 83 | 189 | 158 | ||||||||||||
Avelox |
61 | 59 | 167 | 165 | ||||||||||||
Noxafil |
56 | 50 | 110 | 99 | ||||||||||||
Rebetol |
48 | 55 | 100 | 111 | ||||||||||||
Crixivan/Stocrin |
50 | 48 | 95 | 100 | ||||||||||||
Neurosciences and Ophthalmology |
||||||||||||||||
Maxalt |
131 | 133 | 304 | 268 | ||||||||||||
Cosopt/Trusopt |
122 | 123 | 236 | 238 | ||||||||||||
Oncology |
||||||||||||||||
Temodar |
234 | 271 | 481 | 545 | ||||||||||||
Emend |
120 | 93 | 207 | 177 | ||||||||||||
Intron A |
47 | 51 | 96 | 105 | ||||||||||||
Respiratory and Immunology |
||||||||||||||||
Singulair |
1,354 | 1,258 | 2,682 | 2,423 | ||||||||||||
Remicade |
842 | 669 | 1,595 | 1,343 | ||||||||||||
Nasonex |
323 | 338 | 696 | 658 | ||||||||||||
Clarinex |
209 | 191 | 364 | 355 | ||||||||||||
Arcoxia |
100 | 95 | 214 | 190 | ||||||||||||
Simponi |
75 | 18 | 129 | 28 | ||||||||||||
Asmanex |
47 | 56 | 107 | 107 | ||||||||||||
Proventil |
37 | 55 | 80 | 112 | ||||||||||||
Dulera |
25 | | 37 | | ||||||||||||
Vaccines (1) |
||||||||||||||||
ProQuad/M-M-R II/Varivax |
291 | 340 | 535 | 659 | ||||||||||||
Gardasil |
277 | 219 | 490 | 451 | ||||||||||||
RotaTeq |
148 | 139 | 272 | 231 | ||||||||||||
Zostavax |
122 | 18 | 146 | 114 | ||||||||||||
Pneumovax |
64 | 59 | 143 | 110 | ||||||||||||
Womens Health and Endocrine |
||||||||||||||||
Fosamax |
221 | 241 | 429 | 472 | ||||||||||||
NuvaRing |
154 | 145 | 297 | 280 | ||||||||||||
Follistim AQ |
143 | 137 | 276 | 270 | ||||||||||||
Implanon |
81 | 51 | 141 | 101 | ||||||||||||
Cerazette |
66 | 49 | 125 | 104 | ||||||||||||
Other pharmaceutical (2) |
948 | 941 | 1,697 | 1,888 | ||||||||||||
Total Pharmaceutical segment sales |
10,360 | 9,638 | 20,179 | 19,303 | ||||||||||||
Other segment sales (3) |
1,665 | 1,525 | 3,275 | 3,095 | ||||||||||||
Total segment sales |
12,025 | 11,163 | 23,454 | 22,398 | ||||||||||||
Other (4) |
126 | 183 | 278 | 370 | ||||||||||||
$ | 12,151 | $ | 11,346 | $ | 23,732 | $ | 22,768 | |||||||||
(1) | These amounts do not reflect sales of vaccines sold in most major European
markets through the Companys joint venture, Sanofi Pasteur MSD, the results of which are
reflected in Equity income from affiliates. These amounts do, however, reflect supply sales
to Sanofi Pasteur MSD. |
|
(2) | Other pharmaceutical primarily includes sales of other human pharmaceutical
products, including products within the franchises not listed separately. |
|
(3) | Reflects other non-reportable segments, including Animal Health and Consumer Care,
and revenue from the Companys relationship with AZLP primarily relating to sales of Nexium,
as well as Prilosec. Revenue from AZLP was $306 million and $241 million for the second
quarter of 2011 and 2010, respectively, and $628 million and $605 million for the first six
months of 2011 and 2010, respectively. |
|
(4) | Other revenues are primarily comprised of miscellaneous corporate revenues,
third-party manufacturing sales, sales related to divested products or businesses and other
supply sales not included in segment results. |
- 34 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Segment profits |
$ | 7,098 | $ | 6,614 | $ | 14,030 | $ | 13,074 | ||||||||
Other profits |
58 | 50 | 35 | 62 | ||||||||||||
Adjustments |
257 | 125 | 476 | 249 | ||||||||||||
Unallocated: |
||||||||||||||||
Interest income |
51 | 22 | 92 | 34 | ||||||||||||
Interest expense |
(182 | ) | (185 | ) | (368 | ) | (366 | ) | ||||||||
Equity income from affiliates |
(39 | ) | (47 | ) | 15 | | ||||||||||
Depreciation and amortization |
(623 | ) | (786 | ) | (1,194 | ) | (1,286 | ) | ||||||||
Research and development |
(1,936 | ) | (2,179 | ) | (4,094 | ) | (4,230 | ) | ||||||||
Amortization of purchase
accounting adjustments |
(1,363 | ) | (1,662 | ) | (2,943 | ) | (4,036 | ) | ||||||||
Restructuring costs |
(668 | ) | (526 | ) | (654 | ) | (814 | ) | ||||||||
Arbitration settlement charge |
| | (500 | ) | | |||||||||||
Gain on AstraZeneca option exercise |
| 443 | | 443 | ||||||||||||
Other expenses, net |
(981 | ) | (628 | ) | (1,494 | ) | (1,274 | ) | ||||||||
$ | 1,672 | $ | 1,241 | $ | 3,401 | $ | 1,856 | |||||||||
- 35 -
- 36 -
- 37 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Pharmaceutical: |
||||||||||||||||
Cardiovascular |
||||||||||||||||
Zetia |
$ | 592 | $ | 564 | $ | 1,174 | $ | 1,098 | ||||||||
Vytorin |
459 | 490 | 939 | 967 | ||||||||||||
Integrilin |
56 | 70 | 120 | 140 | ||||||||||||
Diabetes and Obesity |
||||||||||||||||
Januvia |
779 | 600 | 1,518 | 1,111 | ||||||||||||
Janumet |
321 | 218 | 626 | 419 | ||||||||||||
Diversified Brands |
||||||||||||||||
Cozaar/Hyzaar |
406 | 485 | 832 | 1,267 | ||||||||||||
Zocor |
107 | 117 | 234 | 233 | ||||||||||||
Propecia |
112 | 113 | 218 | 213 | ||||||||||||
Claritin Rx |
65 | 58 | 186 | 157 | ||||||||||||
Remeron |
57 | 59 | 117 | 110 | ||||||||||||
Vasotec/Vaseretic |
59 | 63 | 116 | 122 | ||||||||||||
Proscar |
53 | 56 | 113 | 114 | ||||||||||||
Infectious Disease |
||||||||||||||||
Isentress |
337 | 267 | 629 | 499 | ||||||||||||
Cancidas |
168 | 150 | 326 | 303 | ||||||||||||
PegIntron |
154 | 185 | 319 | 371 | ||||||||||||
Primaxin |
136 | 158 | 272 | 317 | ||||||||||||
Invanz |
103 | 83 | 189 | 158 | ||||||||||||
Avelox |
61 | 59 | 167 | 165 | ||||||||||||
Noxafil |
56 | 50 | 110 | 99 | ||||||||||||
Rebetol |
48 | 55 | 100 | 111 | ||||||||||||
Crixivan/Stocrin |
50 | 48 | 95 | 100 | ||||||||||||
Neurosciences and Ophthalmology |
||||||||||||||||
Maxalt |
131 | 133 | 304 | 268 | ||||||||||||
Cosopt/Trusopt |
122 | 123 | 236 | 238 | ||||||||||||
Oncology |
||||||||||||||||
Temodar |
234 | 271 | 481 | 545 | ||||||||||||
Emend |
120 | 93 | 207 | 177 | ||||||||||||
Intron A |
47 | 51 | 96 | 105 | ||||||||||||
Respiratory and Immunology |
||||||||||||||||
Singulair |
1,354 | 1,258 | 2,682 | 2,423 | ||||||||||||
Remicade |
842 | 669 | 1,595 | 1,343 | ||||||||||||
Nasonex |
323 | 338 | 696 | 658 | ||||||||||||
Clarinex |
209 | 191 | 364 | 355 | ||||||||||||
Arcoxia |
100 | 95 | 214 | 190 | ||||||||||||
Simponi |
75 | 18 | 129 | 28 | ||||||||||||
Asmanex |
47 | 56 | 107 | 107 | ||||||||||||
Proventil |
37 | 55 | 80 | 112 | ||||||||||||
Dulera |
25 | | 37 | | ||||||||||||
Vaccines (1) |
||||||||||||||||
ProQuad/M-M-R II/Varivax |
291 | 340 | 535 | 659 | ||||||||||||
Gardasil |
277 | 219 | 490 | 451 | ||||||||||||
RotaTeq |
148 | 139 | 272 | 231 | ||||||||||||
Zostavax |
122 | 18 | 146 | 114 | ||||||||||||
Pneumovax |
64 | 59 | 143 | 110 | ||||||||||||
Womens Health and Endocrine |
||||||||||||||||
Fosamax |
221 | 241 | 429 | 472 | ||||||||||||
NuvaRing |
154 | 145 | 297 | 280 | ||||||||||||
Follistim AQ |
143 | 137 | 276 | 270 | ||||||||||||
Implanon |
81 | 51 | 141 | 101 | ||||||||||||
Cerazette |
66 | 49 | 125 | 104 | ||||||||||||
Other pharmaceutical (2) |
948 | 941 | 1,697 | 1,888 | ||||||||||||
Total Pharmaceutical segment sales |
10,360 | 9,638 | 20,179 | 19,303 | ||||||||||||
Other segment sales (3) |
1,665 | 1,525 | 3,275 | 3,095 | ||||||||||||
Total segment sales |
12,025 | 11,163 | 23,454 | 22,398 | ||||||||||||
Other (4) |
126 | 183 | 278 | 370 | ||||||||||||
$ | 12,151 | $ | 11,346 | $ | 23,732 | $ | 22,768 | |||||||||
(1) | These amounts do not reflect sales of vaccines sold in most major European
markets through the Companys joint venture, Sanofi Pasteur MSD, the results of which are
reflected in Equity income from affiliates. These amounts do, however, reflect supply sales
to Sanofi Pasteur MSD. |
|
(2) | Other pharmaceutical primarily includes sales of other human pharmaceutical
products, including products within the franchises not listed separately. |
|
(3) | Reflects other non-reportable segments, including Animal Health and Consumer Care,
and revenue from the Companys relationship with AZLP primarily relating to sales of Nexium,
as well as Prilosec. Revenue from AZLP was $306 million and $241 million for the second
quarter of 2011 and 2010, respectively, and was $628 million and $605 million for the first
six months of 2011 and 2010, respectively. |
|
(4) | Other revenues are primarily comprised of miscellaneous corporate revenues,
third-party manufacturing sales, sales related to divested products or businesses and other
supply sales not included in segment results. |
- 38 -
- 39 -
- 40 -
- 41 -
- 42 -
- 43 -
- 44 -
- 45 -
- 46 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Pharmaceutical segment profits |
$ | 6,443 | $ | 5,987 | $ | 12,659 | $ | 11,727 | ||||||||
Other non-reportable segment profits |
655 | 627 | 1,371 | 1,347 | ||||||||||||
Other |
(5,426 | ) | (5,373 | ) | (10,629 | ) | (11,218 | ) | ||||||||
Income before income taxes |
$ | 1,672 | $ | 1,241 | $ | 3,401 | $ | 1,856 | ||||||||
- 47 -
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
($ in millions, except per share amounts) | 2011 | 2010 | 2011 | 2010 | ||||||||||||
Pretax income as reported under GAAP |
$ | 1,672 | $ | 1,241 | $ | 3,401 | $ | 1,856 | ||||||||
Increase (decrease) for excluded items: |
||||||||||||||||
Acquisition-related costs |
1,440 | 1,747 | 3,097 | 4,207 | ||||||||||||
Costs related to restructuring programs |
816 | 894 | 942 | 1,245 | ||||||||||||
Other items: |
||||||||||||||||
Arbitration settlement charge |
| | 500 | | ||||||||||||
Loss (gain) on sale of manufacturing
facilities and related assets |
7 | | (127 | ) | | |||||||||||
Gain on AstraZeneca asset option exercise |
| (443 | ) | | (443 | ) | ||||||||||
3,935 | 3,439 | 7,813 | 6,865 | |||||||||||||
Taxes on income as reported under GAAP |
(382 | ) | 461 | 276 | 746 | |||||||||||
Estimated tax benefit on excluded items |
407 | 242 | 738 | 892 | ||||||||||||
Tax benefit from settlement of federal income tax audit |
700 | | 700 | | ||||||||||||
Tax benefit from foreign and state tax rate changes |
230 | | 230 | | ||||||||||||
Tax charge related to U.S. health care reform legislation |
| | | (147 | ) | |||||||||||
955 | 703 | 1,944 | 1,491 | |||||||||||||
Non-GAAP net income |
2,980 | 2,736 | 5,869 | 5,374 | ||||||||||||
Less: Net income attributable to noncontrolling interests |
30 | 28 | 58 | 59 | ||||||||||||
Non-GAAP net income attributable to Merck & Co., Inc. |
$ | 2,950 | $ | 2,708 | $ | 5,811 | $ | 5,315 | ||||||||
EPS assuming dilution as reported under GAAP |
$ | 0.65 | $ | 0.24 | $ | 0.98 | $ | 0.33 | ||||||||
EPS difference (1) |
0.30 | 0.62 | 0.89 | 1.36 | ||||||||||||
Non-GAAP EPS assuming dilution |
$ | 0.95 | $ | 0.86 | $ | 1.87 | $ | 1.69 | ||||||||
(1) | Represents the difference between calculated GAAP EPS and calculated non-GAAP
EPS, which may be different than the amount calculated by dividing the impact of the excluded
items by the weighted average shares for the applicable period. |
- 48 -
- 49 -
Phase II | Phase III (Phase III entry date) | Under Review | ||
Allergy
MK-8237 (SCH 900237), Immunotherapy(1) Cancer
MK-0646 (dalotuzumab) MK-7965 (SCH 727965) (dinaciclib) Clostridium difficile Infection
MK-3415A Contraception, Medicated IUS
MK-8342 (SCH 900342) COPD
MK-7123 (SCH 527123) (navarixin) Diabetes Mellitus
MK-3102 Hepatitis C
MK-5172 Insomnia
MK-3697 MK-6096 Osteoporosis
MK-5442 Overactive Bladder
MK-4618 Pneumoconjugate Vaccine
V114 Progeria
MK-6336 (SCH 066336) (lonafarnib) Psoriasis
MK-3222 (SCH 900222) |
Allergy
MK-7243 (SCH 697243), Grass pollen(1) (March 2008) MK-3641 (SCH 039641), Ragweed(1) (September 2009) Atherosclerosis
MK-0524A (extended-release niacin/laropiprant) (U.S.) (December 2005) MK-0524B (extended-release niacin/laropiprant/simvastatin) (July 2007) MK-0859 (anacetrapib) (May 2008) Atrial Fibrillation
MK-6621 (vernakalant i.v.) (U.S.) (August 2003) (2) Cervical Cancer
V503 (HPV vaccine (9 valent)) (September 2008) COPD
MK-0887A (SCH 418131) (Zenhale) (EU) (August 2006) Diabetes
MK-0431C (sitagliptin/pioglitazone) (September 2008) Fertility
MK-8962 (SCH 900962) (corifollitropin alfa injection) (U.S.) (July 2006) Hepatitis C
MK-7009 (vaniprevir)(3) (June 2011) Herpes Zoster
V212 (inactivated VZV vaccine) (December 2010) Insomnia
MK-4305 (suvorexant) (December 2009) Neuromuscular Blockade Reversal
MK-8616 (SCH 900616) (Bridion) (U.S.) (November 2005) Osteoporosis
MK-0822 (odanacatib) (September 2007) Parkinsons Disease
MK-3814 (SCH 420814) (preladenant) (July 2010) Pediatric Hexavalent Combination Vaccine
V419 (April 2011) Sarcoma
MK-8669 (ridaforolimus) (October 2007) Thrombosis
MK-5348 (SCH 530348) (vorapaxar) (September 2007) |
Atherosclerosis
MK-0653C (ezetimibe/atorvastatin) (U.S.) Contraception
MK-8175A (SCH 900121) (Zoely) (NOMAC/E2) (EU) (U.S.) Diabetes
MK-0431D (sitagliptin/simvastatin) (U.S.) MK-0431A XR (sitagliptin/extended-release metformin) (U.S.) (4) Glaucoma
MK-2452 (tafluprost) (U.S.) Footnotes: (1) North American rights only. (2) Vernakalant i.v. for atrial fibrillation started Phase III clinical trials in August 2003 sponsored by Cardiome in collaboration with Astellas. (3) For development in Japan only. (4) In July 2011, Merck received a Complete Response letter from the FDA. |
- 50 -
June 30, | December 31, | |||||||
($ in millions) | 2011 | 2010 | ||||||
Cash and investments |
$ | 16,156 | $ | 14,376 | ||||
Working capital |
16,605 | 13,423 | ||||||
Total debt to total liabilities and equity |
17.2 | % | 16.9 | % | ||||
- 51 -
- 52 -
- 53 -
($ in millions) | ||||||||||||
Total Number | Average Price | Approximate Dollar Value of Shares | ||||||||||
of Shares | Paid Per | That May Yet Be Purchased | ||||||||||
Period | Purchased(1) | Share | Under the Plans or Programs(1) | |||||||||
April 1 - April 30, 2011 |
0 | | $ | 6,407 | ||||||||
May 1 - May 31, 2011 |
3,451,700 | $ | 36.90 | $ | 6,279 | |||||||
June 1 - June 30, 2011 |
5,275,900 | $ | 35.48 | $ | 6,092 | |||||||
Total |
8,727,600 | $ | 36.04 | $ | 6,092 |
(1) | All shares purchased during the period were made as part of plans approved by
the Board of Directors in November 2009 to purchase up to $3 billion in Merck shares and in April
2011 to purchase up to $5 billion in Merck shares. |
- 54 -
Number | Description | |
3.1
|
Restated Certificate of Incorporation of Merck & Co., Inc. (November
3, 2009) Incorporated by reference to Current Report on Form 8-K
filed on November 4, 2009 |
|
3.2
|
By-Laws of Merck & Co., Inc. (effective November 3, 2009)
Incorporated by reference to Current Report on Form 8-K filed November
4, 2009 |
|
31.1
|
Rule 13a 14(a)/15d 14(a) Certification of Chief Executive Officer |
|
31.2
|
Rule 13a 14(a)/15d 14(a) Certification of Chief Financial Officer |
|
32.1
|
Section 1350 Certification of Chief Executive Officer |
|
32.2
|
Section 1350 Certification of Chief Financial Officer |
|
101
|
The following materials from Merck & Co., Inc.s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL
(Extensible Business Reporting Language): (i) the Consolidated
Statement of Income, (ii) the Consolidated Balance Sheet, (iii) the
Consolidated Statement of Cash Flow, and (iv) Notes to Consolidated
Financial Statements. |
- 55 -
MERCK & CO., INC. |
||||
Date: August 8, 2011 | /s/ Bruce N. Kuhlik | |||
BRUCE N. KUHLIK | ||||
Executive Vice President and General Counsel | ||||
Date: August 8, 2011 | /s/ John Canan | |||
JOHN CANAN | ||||
Senior Vice President Finance - Global Controller |
- 56 -
Number | Description | |
3.1
|
Restated Certificate of Incorporation of Merck & Co., Inc. (November
3, 2009) Incorporated by reference to Current Report on Form 8-K
filed on November 4, 2009 |
|
3.2
|
By-Laws of Merck & Co., Inc. (effective November 3, 2009)
Incorporated by reference to Current Report on Form 8-K filed November
4, 2009 |
|
31.1
|
Rule 13a 14(a)/15d 14(a) Certification of Chief Executive Officer |
|
31.2
|
Rule 13a 14(a)/15d 14(a) Certification of Chief Financial Officer |
|
32.1
|
Section 1350 Certification of Chief Executive Officer |
|
32.2
|
Section 1350 Certification of Chief Financial Officer |
|
101
|
The following materials from Merck & Co., Inc.s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL
(Extensible Business Reporting Language): (i) the Consolidated
Statement of Income, (ii) the Consolidated Balance Sheet, (iii) the
Consolidated Statement of Cash Flow, and (iv) Notes to Consolidated
Financial Statements. |
- 57 -
By: | /s/ Kenneth C. Frazier | |||
KENNETH C. FRAZIER | ||||
President and Chief Executive Officer |
By: | /s/ Peter N. Kellogg | |||
PETER N. KELLOGG | ||||
Executive Vice President & Chief Financial Officer |
Dated: August 8, 2011 | /s/ Kenneth C. Frazier | |||
Name: | KENNETH C. FRAZIER | |||
Title: | President and Chief Executive Officer |
Dated: August 8, 2011 | /s/ Peter N. Kellogg | |||
Name: | PETER N. KELLOG | |||
Title: | Executive Vice President & Chief Financial Officer |
|||
Equity (Textuals) (Details) (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Stockholders' Equity (Textuals) [Abstract] | ||||
Par value preferred stock assumed in connection with the 1998 restructuring of Astra Merck Inc | $ 2,400,000,000 | $ 2,400,000,000 | ||
Preferred stock assumed with Astra Merck Inc., dividend rate per annum | 5% per annum | |||
Comprehensive income (loss) | 2,400,000,000 | (335,000,000) | 3,500,000,000 | (841,000,000) |
Cumulative translation gains (losses) relating to translation impact of intangible assets | 340,000,000 | (2,100,000,000) | ||
Designated as, and are effective as, economic hedges of the net investment in a foreign operation [Member]
|
||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Cumulative translation pretax gains (losses) from euro denominated notes | $ (178,000,000) | $ 462,000,000 | $ (178,000,000) | $ 462,000,000 |
Consolidated Balance Sheet (Unaudited) (Parenthetical) (USD $)
In Millions, except Share data |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Current Assets | ||
Allowance for doubtful accounts | $ 128 | $ 104 |
Inventories classified in Other assets | 1,408 | 1,194 |
Accumulated depreciation | $ 15,195 | $ 13,481 |
Merck & Co., Inc. Stockholders' Equity | ||
Common stock, par value | $ 0.50 | $ 0.50 |
Common stock, shares authorized | 6,500,000,000 | 6,500,000,000 |
Common stock, shares issued | 3,576,948,356 | 3,576,948,356 |
Treasury stock, shares | 493,935,906 | 494,841,533 |
Restructuring (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Charges related to Merger Restructuring Program and 2008 Restructuring Program activities by type of cost |
The following tables summarize the charges related to Merger Restructuring Program and 2008
Restructuring Program activities by type of cost:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Charges and spending relating to Merger Restructuring Program and 2008 Restructuring Program activities |
The following table summarizes the charges and spending relating to Merger Restructuring
Program and 2008 Restructuring Program activities for the six months ended June 30, 2011:
|
Document and Entity Information (USD $)
|
6 Months Ended | ||
---|---|---|---|
Jun. 30, 2011
|
Jul. 29, 2011
|
Jun. 30, 2010
|
|
Document and Entity Information [Abstract] | |||
Entity Registrant Name | Merck & Co. Inc. | ||
Entity Central Index Key | 0000310158 | ||
Document Type | 10-Q | ||
Document Period End Date | Jun. 30, 2011 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2011 | ||
Document Fiscal Period Focus | Q2 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well Known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 107,724,000,000 | ||
Entity Common Stock, Shares Outstanding | 3,080,796,992 |
Equity (Details) (USD $)
In Millions, except Share data |
3 Months Ended | 6 Months Ended | 6 Months Ended | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2010
Common Stock [Member]
|
Jun. 30, 2011
Common Stock [Member]
|
Dec. 31, 2010
Common Stock [Member]
|
Jun. 30, 2011
Other Paid-In Capital [Member]
|
Jun. 30, 2010
Other Paid-In Capital [Member]
|
Jun. 30, 2011
Retained Earnings [Member]
|
Jun. 30, 2010
Retained Earnings [Member]
|
Jun. 30, 2011
Accumulated Other Comprehensive Loss [Member]
|
Jun. 30, 2010
Accumulated Other Comprehensive Loss [Member]
|
Jun. 30, 2011
Treasury Stock [Member]
|
Jun. 30, 2010
Treasury Stock [Member]
|
Jun. 30, 2011
Noncontrolling Interests [Member]
|
Jun. 30, 2010
Noncontrolling Interests [Member]
|
|
Stockholders' Equity | |||||||||||||||||
Beginning balance | $ 56,805 | $ 61,485 | $ 1,781 | $ 1,788 | $ 1,788 | $ 40,701 | $ 39,683 | $ 37,536 | $ 41,405 | $ (3,216) | $ (2,767) | $ (22,433) | $ (21,044) | $ 2,429 | $ 2,427 | ||
Beginning balance, shares | 3,576,948,356 | 3,563,000,000 | 3,577,000,000 | 3,577,000,000 | 495,000,000 | 454,000,000 | |||||||||||
Net Income Attributable to Merck & Co., Inc. | 2,024 | 752 | 3,067 | 1,051 | 3,067 | 1,051 | |||||||||||
Cash dividends declared on common stock | (2,360) | (2,374) | (2,360) | (2,374) | |||||||||||||
Treasury stock, shares purchased | 9,000,000 | 38,000,000 | |||||||||||||||
Treasury stock shares purchased | (314) | (1,297) | (314) | (1,297) | |||||||||||||
Share-based compensation plans and other | 287 | 685 | 5 | (44) | 655 | 331 | 25 | ||||||||||
Share-based compensation plans and other, shares | 10,000,000 | (10,000,000) | |||||||||||||||
Other comprehensive loss | 440 | (1,892) | 440 | (1,892) | |||||||||||||
Net income attributable to noncontrolling interests | 30 | 28 | 58 | 59 | 58 | 59 | |||||||||||
Distributions attributable to noncontrolling interests | (61) | (60) | (61) | (60) | |||||||||||||
Ending balance | $ 57,922 | $ 57,657 | $ 57,922 | $ 57,657 | $ 1,786 | $ 1,788 | $ 1,788 | $ 40,657 | $ 40,338 | $ 38,243 | $ 40,082 | $ (2,776) | $ (4,659) | $ (22,416) | $ (22,316) | $ 2,426 | $ 2,426 |
Ending balance, shares | 3,576,948,356 | 3,576,948,356 | 3,573,000,000 | 3,577,000,000 | 3,577,000,000 | 494,000,000 | 492,000,000 |
Joint Ventures and Other Equity Method Affiliates (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Joint Ventures and Other Equity Method Affiliates [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity income from affiliates |
Equity income from affiliates reflects the performance of the Company’s joint ventures and
other equity method affiliates and was comprised of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summarized financial information for AZLP |
Summarized financial information for AZLP is as follows:
|
Contingencies (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 6 Months Ended | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 30, 2011
|
Jun. 30, 2011
Defendants
Derivatives
|
Jun. 30, 2010
|
Jun. 30, 2011
Years
Derivatives
Plaintiffs
Segments
Defendants
|
Jun. 30, 2010
|
Dec. 31, 2010
Remicade and Simponi [Member]
|
Jun. 30, 2011
Fosamax [Member]
Plaintiffs
Claims
|
Dec. 31, 2010
Fosamax [Member]
ONJ Litigation [Member]
|
Jun. 30, 2011
Fosamax [Member]
ONJ Litigation [Member]
Claims
|
Jun. 30, 2011
Fosamax [Member]
ONJ Litigation [Member]
New Jersey [Member]
Claims
|
Jun. 30, 2011
Fosamax [Member]
Other Bone Injury [Member]
Claims
|
Jun. 30, 2011
Fosamax [Member]
Other Bone Injury [Member]
New Jersey [Member]
Claims
|
Jun. 30, 2011
NuvaRing [Member]
Claims
|
Jun. 30, 2011
NuvaRing [Member]
New Jersey [Member]
Claims
|
Jun. 30, 2011
DOJ and EPA Matters [Member]
|
Dec. 31, 2010
Department of Justice [Member]
|
Apr. 30, 2011
Johnson & Johnson [Member]
|
Jun. 30, 2011
AWP Litigation and Investigation [Member]
|
Jun. 30, 2011
Vytorin shareholder lawsuits [Member]
|
Jun. 30, 2011
Vytorin ERISA lawsuits [Member]
|
Jun. 30, 2011
Vioxx Litigation [Member]
|
Jun. 30, 2011
Vioxx Litigation [Member]
|
Dec. 31, 2010
Vioxx Litigation [Member]
|
Jun. 30, 2011
Vioxx Product Liability [Member]
PlaintiffGroups
|
Jun. 30, 2011
Other Vioxx Lawsuits [Member]
Claims
|
Jun. 30, 2011
Vioxx Securities Lawsuit [Member]
|
Jun. 30, 2011
Vioxx ERISA Lawsuits [Member]
|
|
Loss Contingencies [Line Items] | |||||||||||||||||||||||||||
Number of cases pending against the Company | 1,650 | 1,115 | 535 | 815 | |||||||||||||||||||||||
Number of plaintiff groups | 2,050 | ||||||||||||||||||||||||||
Number of lawsuits in federal court | 910 | 690 | 30 | ||||||||||||||||||||||||
Number of lawsuits in New Jersey state court | 190 | 430 | 122 | ||||||||||||||||||||||||
Plaintiff Groups eligible for the Settlement Program, claims remain pending | 30 | ||||||||||||||||||||||||||
Plaintiff groups not eligible for Settlement Program claims remain pending | 100 | ||||||||||||||||||||||||||
Upper limit of directors and officers insurance coverage | $ 250,000,000 | $ 265,000,000 | $ 175,000,000 | $ 275,000,000 | |||||||||||||||||||||||
Gain (loss) recorded related to legal contingency | (500,000,000) | (950,000,000) | |||||||||||||||||||||||||
Amount of Vioxx legal defense costs reserve | 58,000,000 | 58,000,000 | 76,000,000 | ||||||||||||||||||||||||
Charge recorded for future legal defense costs | 19,000,000 | 19,000,000 | |||||||||||||||||||||||||
Initial group of cases to complete fact discovery | 25 | ||||||||||||||||||||||||||
Number of cases pending in other state courts | 3 | 4 | |||||||||||||||||||||||||
Trial pool cases which are the subject of fact discovery | 26 | ||||||||||||||||||||||||||
Additional trial pool cases selected | 10 | ||||||||||||||||||||||||||
Sales | 12,151,000,000 | 11,346,000,000 | 23,732,000,000 | 22,768,000,000 | 2,800,000,000 | ||||||||||||||||||||||
Verdict amount in favor of the plaintiff | 8,000,000 | 13,800,000 | |||||||||||||||||||||||||
Reduced verdict amount | 1,500,000 | ||||||||||||||||||||||||||
Contribution income (profit) split to partner | 42.00% | ||||||||||||||||||||||||||
Aggregate amount spent in legal defense costs worldwide related to Vioxx Litigation | 21,000,000 | 37,000,000 | |||||||||||||||||||||||||
Amount of one-time legal settlement payment | 500,000,000 | 500,000,000 | |||||||||||||||||||||||||
Civil penalties sought against Merck by DOJ and EPA | 2,000,000 | ||||||||||||||||||||||||||
Payments for fines for environmental matters | $ 260,000 | ||||||||||||||||||||||||||
Contingencies and Environmental Liabilities (Textuals) [Abstract] | |||||||||||||||||||||||||||
Revenue percentage represented by retained territories | 70.00% | ||||||||||||||||||||||||||
Contribution income (profit) split to Company | 58.00% | ||||||||||||||||||||||||||
Revenue percentage represented by relinquished territories | 30.00% | ||||||||||||||||||||||||||
Number of plaintiffs filed amended complaint | 2,200 | ||||||||||||||||||||||||||
Number of other defendants in environmental matters | 12 | 12 | |||||||||||||||||||||||||
Number of other defendants in phase 1 trial | 3 | 3 |
"+ text.join( "
\n" ) +"
" + text[p] + "
\n"; } } }else{ formatted = '' + raw + '
'; } html = ''+ "\n"+''+ "\n"+''+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+' | '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
Other Intangibles
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Other Intangibles [Abstract] | |
Other intangibles |
7. Other Intangibles
At the time of the Merger, the Company measured the fair value of Schering-Plough’s marketed
products and legacy pipeline programs and capitalized these amounts. During the second quarter of
2011, the Company recorded an intangible asset impairment charge of $118 million within Materials and
production costs related to a marketed product. Also, during the second quarter and first six
months of 2011, the Company recorded $19 million and $321 million, respectively, of in-process
research and development (“IPR&D”) impairment charges within
Research and development expenses primarily for pipeline programs that had previously been
deprioritized and were deemed to have no alternative use in the period. During the first six
months of 2010, the Company recorded $27 million of IPR&D impairment charges attributable to
compounds identified during the Company’s pipeline prioritization review that were abandoned and
determined to have either no alternative use or were returned to the respective licensor. The
Company may recognize additional non-cash impairment charges in the future related to marketed
products or for the cancellation of other legacy Schering-Plough pipeline programs and such charges
could be material.
|
Equity (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated balances related to each component of other comprehensive income (loss) |
The accumulated balances related to each component of other comprehensive income (loss), net
of taxes, were as follows:
|
Other Intangibles (Details) (USD $)
In Millions |
3 Months Ended | 6 Months Ended | |
---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Other Intangibles (Textuals) [Abstract] | |||
Finite-lived Intangible asset impairment charges | $ 118 | $ 118 | |
Impairment charges associated with in-process research and development | $ 19 | $ 321 | $ 27 |
Inventories (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
Inventories consisted of:
|
Pension and Other Postretirement Benefit Plans
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Other Postretirement Benefit Plans [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Other Postretirement Benefits Plans |
12. Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States
and in certain of its international subsidiaries. The net cost of such plans consisted of the
following components:
The Company provides medical, dental and life insurance benefits, principally to its eligible
U.S. retirees and similar benefits to their dependents, through its other postretirement benefit
plans. The net cost of such plans consisted of the following components:
In connection with restructuring actions (see Note 2), termination charges for the three and
six months ended June 30, 2011 and 2010 were recorded on pension and other postretirement benefit
plans related to expanded eligibility for certain employees exiting Merck. Also, in connection
with these restructuring actions, curtailments were recorded on pension and other postretirement
benefit plans and settlements were recorded on pension plans as reflected in the tables above.
|
Acquisitions, Divestitures, Research Collaborations and License Agreements
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Acquisitions, Divestitures, Research Collaborations and License Agreements [Abstract] | |
Acquisitions, Divestitures, Research Collaborations and License Agreements |
3. Acquisitions, Divestitures, Research Collaborations and License Agreements
In May 2011, Merck completed the acquisition of Inspire Pharmaceuticals, Inc. (“Inspire”), a
specialty pharmaceutical company focused on developing and commercializing ophthalmic products.
Under the terms of the merger agreement, Merck acquired all outstanding shares of common stock of
Inspire at a price of $5.00 per share in cash for a total of approximately $420 million. The
transaction was accounted for as an acquisition of a business; accordingly, the assets
acquired and liabilities assumed were recorded at their respective fair values as of the
acquisition date. The determination of fair value requires management to make significant
estimates and assumptions. In connection with the acquisition, substantially all of the purchase
price was allocated to Inspire’s product and product right intangible assets and related deferred
tax liabilities, a deferred tax asset relating to Inspire’s net operating loss carryforwards, and goodwill. Certain estimated values are not yet finalized
and may be subject to change. The Company expects to finalize these amounts as soon as possible,
but no later than one year from the acquisition date. This transaction closed on May 16, 2011, and
accordingly, the results of operations of the acquired business have been included in the Company’s
results of operations beginning after the acquisition date. Pro forma financial information has
not been included because Inspire’s historical financial results are not significant when compared
with the Company’s financial results.
In March 2011, the Company sold the Merck BioManufacturing Network, a leading provider of
contract manufacturing and development services for the biopharmaceutical industry and wholly owned
by Merck, to Fujifilm Corporation (“Fujifilm”). Under the
terms of the agreement, Fujifilm purchased all of the equity interests in two Merck subsidiaries which together own all assets of the
Merck BioManufacturing Network comprising facilities located in Research Triangle Park, North
Carolina and Billingham, U.K.; and including manufacturing contracts; business support operations
and a highly skilled workforce. As part of the agreement with Fujifilm, Merck has committed to
certain continued development and manufacturing activities with these two companies. The
transaction resulted in a gain of $127 million in the first six
months of 2011 reflected in Other (income) expense, net.
|
Restructuring (Details Textuals) (USD $)
|
3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
Merger Restructuring Program [Member]
Minimum [Member]
|
Jul. 31, 2011
Minimum [Member]
|
Jun. 30, 2011
2008 Global Restructuring Program [Member]
Maximum [Member]
|
Jun. 30, 2011
Merger Restructuring Program [Member]
Maximum [Member]
|
Jul. 31, 2011
Maximum [Member]
|
Jun. 30, 2011
2008 Global Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2010
2008 Global Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2011
2008 Global Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2010
2008 Global Restructuring Program [Member]
EmployeePositions
|
Dec. 31, 2010
2008 Global Restructuring Program [Member]
|
Jun. 30, 2011
Merger Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2010
Merger Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2011
Merger Restructuring Program [Member]
EmployeePositions
|
Jun. 30, 2010
Merger Restructuring Program [Member]
EmployeePositions
|
Dec. 31, 2010
Merger Restructuring Program [Member]
|
Jun. 30, 2011
Legacy Schering-Plough Program [Member]
|
Jun. 30, 2010
Legacy Schering-Plough Program [Member]
|
Jun. 30, 2011
Legacy Schering-Plough Program [Member]
|
Jun. 30, 2010
Legacy Schering-Plough Program [Member]
|
|
Restructuring (Textuals) [Abstract] | |||||||||||||||||||||||
Total pretax restructuring costs | $ 809,000,000 | $ 896,000,000 | $ 926,000,000 | $ 1,244,000,000 | $ 1,000,000 | $ 66,000,000 | $ 5,000,000 | $ 131,000,000 | $ 808,000,000 | $ 830,000,000 | $ 921,000,000 | $ 1,113,000,000 | |||||||||||
Vacant positions eliminated | over 2,500 | ||||||||||||||||||||||
Vacant positions to be eliminated | 400 | ||||||||||||||||||||||
Cumulative restructuring costs incurred to date since program inception | 1,600,000,000 | 4,200,000,000 | |||||||||||||||||||||
Positions eliminated since inception of program | 5,980 | 5,980 | 12,900 | 12,900 | |||||||||||||||||||
Expected cumulative restructuring costs, pre-tax | 5,800,000,000 | 2,000,000,000 | 6,600,000,000 | ||||||||||||||||||||
Percentage estimate of cumulative pretax costs that will result in cash outlays (primarily from employee separation expense) | two-thirds | two-thirds | |||||||||||||||||||||
Percentage estimate of cumulative pretax costs that will be non-cash (primarily from accelerated depreciation of facilities) | one-third | one-third | |||||||||||||||||||||
Total number of position expected to be eliminated | 7,200 | ||||||||||||||||||||||
Number of active employees expected to be eliminated | 6,800 | ||||||||||||||||||||||
Number of positions eliminated | 60 | 240 | 180 | 775 | 585 | 2,435 | 1,335 | 7,585 | |||||||||||||||
Accelerated depreciation | 11,000,000 | 261,000,000 | 7,000,000 | 6,000,000 | 16,000,000 | 9,000,000 | |||||||||||||||||
Gain related to manufacturing facilities | 8,000,000 | 8,000,000 | |||||||||||||||||||||
Restructuring Reserve | 175,000,000 | 175,000,000 | 196,000,000 | 1,255,000,000 | 1,255,000,000 | 923,000,000 | 38,000,000 | 38,000,000 | |||||||||||||||
Expected percentage of reduction in total workforce related to Merger Restructuring Program | 12.00% | 13.00% | 17.00% | ||||||||||||||||||||
Reduction of separation reserves | $ 50,000,000 | ||||||||||||||||||||||
Number of employees to be retained at specified site that were previously expected to be separated | 380 |
Contingencies
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Contingencies [Abstract] | |
Contingencies |
9. Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal
to its business, including product liability, intellectual property, and commercial litigation, as
well as additional matters such as antitrust actions.
Vioxx Litigation
Product Liability Lawsuits
As previously disclosed, individual and putative class actions have been filed against Old
Merck in state and federal courts alleging personal injury and/or economic loss with respect to the
purchase or use of Vioxx. All such actions filed in federal court are coordinated in a
multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana (the
“Vioxx MDL”) before District Judge Eldon E. Fallon. A number of such actions filed in state court
are coordinated in separate coordinated proceedings in state courts
in California and Texas. (All of the actions discussed in this paragraph and in “Other
Lawsuits” below are collectively referred to as the “Vioxx Product Liability Lawsuits.”)
Of the plaintiff groups in the Vioxx Product Liability Lawsuits described above, the vast
majority were dismissed as a result of the Vioxx Settlement Program, which has been described
previously. As of June 30, 2011, approximately 30 plaintiff groups who were otherwise eligible for
the Settlement Program did not participate and their claims remain pending against Old Merck. In
addition, the claims of approximately 100 plaintiff groups who were not eligible for the Settlement
Program remain pending against Old Merck, a number of which are subject to various motions to
dismiss for failure to comply with court-ordered deadlines.
There
are no U.S. Vioxx Product Liability Lawsuits currently scheduled for trial in 2011. Old
Merck has previously disclosed the outcomes of several Vioxx Product Liability Lawsuits that were
tried prior to 2010. Of the cases that went to trial, there are two unresolved post-trial appeals:
Ernst v. Merck and Garza v. Merck. Merck has previously disclosed the details associated with
these cases and the grounds for Merck’s appeals.
Other Lawsuits
There are still pending in various U.S. courts putative class actions purportedly brought on
behalf of individual purchasers or users of Vioxx seeking reimbursement for alleged economic loss.
In the Vioxx MDL proceeding, approximately 30 such class actions remain. In June 2010, Old Merck
moved to strike the class claims or for judgment on the pleadings regarding the master complaint,
which includes the above-referenced cases, and briefing on that motion was completed in September
2010. The Vioxx MDL court heard oral argument on Old Merck’s motion in October 2010, and took it
under advisement.
In June 2008, a Missouri state court certified a class of Missouri plaintiffs seeking
reimbursement for out-of-pocket costs relating to Vioxx. Trial is scheduled to begin on May 21,
2012. In addition, in Indiana, plaintiffs have filed a motion to certify a class of Indiana Vioxx
purchasers in a case pending before the Circuit Court of Marion County, Indiana. In April 2010, a
Kentucky state court denied Old Merck’s motion for summary judgment and certified a class of
Kentucky plaintiffs seeking reimbursement for out-of-pocket costs relating to Vioxx. The Kentucky
Court of Appeals denied Old Merck’s petition for a writ of mandamus, and the Kentucky Supreme Court
has affirmed that ruling. The trial court entered an amended class certification order on January
27, 2011, and Merck has appealed that ruling to the Kentucky Court of Appeals.
Old Merck has also been named as a defendant in several lawsuits brought by, or on behalf of,
government entities. Twelve of these suits are being brought by state Attorneys General and one has
been brought on behalf of a county. All of these actions, except for a suit brought by the
Attorney General of Michigan, are in the Vioxx MDL proceeding. The Michigan Attorney General case
was remanded to state court. The trial court denied Old Merck’s motion to dismiss, but the Court
of Appeals reversed that ruling on March 17, 2011, ordering the trial court to dismiss the case.
The Michigan Attorney General has sought review before the Michigan Supreme Court, and its petition
is currently pending. These actions allege that Old Merck misrepresented the safety of Vioxx. All
but one of these suits seeks recovery for expenditures on Vioxx by government-funded health care
programs such as Medicaid, along with other relief such as penalties and attorneys’ fees. An
action brought by the Attorney General of Kentucky seeks only penalties for alleged Consumer Fraud
Act violations. The lawsuit brought by the county is a class action filed by Santa Clara County,
California on behalf of all similarly situated California counties. Old Merck moved to dismiss the
case brought by the Attorney General of Oklahoma in December 2010.
In March 2010, Judge Fallon partially granted and partially denied Old Merck’s motion for
summary judgment in the Louisiana Attorney General case. A trial on the remaining claims before
Judge Fallon was
completed in April 2010 and Judge Fallon found in favor of Old Merck in June 2010
dismissing the Attorney General’s remaining claims with prejudice. The Louisiana Attorney General
filed a notice of appeal.
Shareholder Lawsuits
As previously disclosed, in addition to the Vioxx Product Liability Lawsuits, various putative
class actions and individual lawsuits under federal and state securities laws have been filed
against Old Merck and various current and former officers and directors (the “Vioxx Securities
Lawsuits”). As previously disclosed, the Vioxx Securities Lawsuits have been transferred by the
Judicial Panel on Multidistrict Litigation (the “JPML”) to the U.S. District Court for the District
of New Jersey before District Judge Stanley R. Chesler for inclusion in a nationwide MDL (the
“Shareholder MDL”), and have been consolidated for all purposes. In June 2010, Old Merck moved to
dismiss the Fifth Amended Class Action Complaint in the consolidated securities action. Oral
argument on the motion to dismiss was held on July 12, 2011.
As previously disclosed, several individual securities lawsuits filed by foreign institutional
investors also are consolidated with the Vioxx Securities Lawsuits. By stipulation, defendants are
not required to respond to these complaints until the resolution of any motions to dismiss in the
consolidated securities class action.
In addition, as previously disclosed, various putative class actions have been filed in
federal court under the Employee Retirement Income Security Act (“ERISA”) against Old Merck and
certain current and former officers and directors (the “Vioxx ERISA Lawsuits”). Those cases were
consolidated in the Shareholder MDL before Judge Chesler. Fact discovery in the Vioxx ERISA
Lawsuits closed in September 2010 and expert discovery closed on May 20, 2011. On June 20, 2011,
Old Merck filed a motion for summary judgment, and plaintiffs filed a motion for partial summary
judgment; those motions will be fully briefed on August 12, 2011. As previously disclosed, in
February 2009, the court denied the motion for class certification as to one count, and granted the
motion as to the remaining counts in Consolidated Amended Complaint in the Vioxx ERISA Lawsuits.
On June 21, 2011, plaintiffs filed a renewed motion for class certification on the count that the
court had previously ruled could not be decided on a class-wide basis; Old Merck filed an
opposition to that renewed motion on July 1, 2011, and plaintiffs filed a reply on July 14, 2011.
The motion is awaiting a decision by the court. Under the scheduling order, a final pre-trial
order is due on November 1, 2011, and a final pre-trial conference is scheduled for November 15,
2011. No trial date has been set.
International Lawsuits
As previously disclosed, in addition to the lawsuits discussed above, Old Merck has been named
as a defendant in litigation relating to Vioxx in Australia, Brazil, Canada, Europe and Israel
(collectively, the “Vioxx Foreign Lawsuits”).
Insurance
The Company has Directors and Officers insurance coverage applicable to the Vioxx Securities
Lawsuits with remaining stated upper limits of approximately $175 million. The Company has
Fiduciary and other insurance for the Vioxx ERISA Lawsuits with stated upper limits of
approximately $275 million. As a result of the previously disclosed insurance arbitration,
additional insurance coverage for these claims should also be available, if needed, under
upper-level excess policies that provide coverage for a variety of risks. There are disputes with
the insurers about the availability of some or all of the Company’s insurance coverage for these
claims and there are likely to be additional disputes. The amounts actually recovered under the
policies discussed in this paragraph may be less than the stated upper limits.
Investigations
As previously disclosed, Old Merck has received subpoenas from the Department of Justice
(“DOJ”) requesting information related to Old Merck’s research, marketing and selling activities
with respect to Vioxx in a federal health care investigation under criminal statutes. This
investigation included subpoenas for witnesses to appear before a grand jury. As previously
disclosed, in March 2009, Old Merck received a letter from the U.S. Attorney’s Office for the
District of Massachusetts identifying it as a target of the grand jury investigation regarding
Vioxx. In the third quarter of 2010, the Company established a $950 million reserve (the “Vioxx
Liability Reserve”) in connection with the anticipated resolution of the DOJ’s investigation. The
Company’s discussions with the government are ongoing. Until they are concluded, there can be no
certainty about a definitive resolution. The
Company is cooperating with the DOJ in its
investigation (the “Vioxx Investigation”). The Company cannot predict the outcome of these
inquiries; however, they could result in potential civil and/or criminal remedies.
Reserves
There
are no U.S. Vioxx Product Liability Lawsuits currently scheduled for trial in 2011. The
Company cannot predict the timing of any other trials related to the Vioxx Litigation (as defined
below). The Company believes that it has meritorious defenses to the Vioxx Product Liability
Lawsuits, Vioxx Shareholder Lawsuits and Vioxx Foreign Lawsuits (collectively, the “Vioxx
Lawsuits”) and will vigorously defend against them. In view of the inherent difficulty of
predicting the outcome of litigation, particularly where there are many claimants and the claimants
seek indeterminate damages, the Company is unable to predict the outcome of these matters, and at
this time cannot reasonably estimate the possible loss or range of loss with respect to the Vioxx
Lawsuits not included in the Settlement Program. Unfavorable outcomes in the Vioxx Litigation
could have a material adverse effect on the Company’s financial position, liquidity and results of
operations.
Legal defense costs expected to be incurred in connection with a loss contingency are accrued
when probable and reasonably estimable.
As of December 31, 2010, the Company had an aggregate
reserve of approximately $76 million (the “Vioxx Legal Defense Costs Reserve”) solely for future
legal defense costs related to the Vioxx Litigation.
During the first six months of 2011, the Company spent approximately $37 million in the
aggregate, including $21 million in the second quarter, in legal defense costs worldwide related to
(i) the Vioxx Product Liability Lawsuits, (ii) the Vioxx Shareholder Lawsuits, (iii) the Vioxx
Foreign Lawsuits, and (iv) the Vioxx Investigation (collectively, the “Vioxx Litigation”). In
addition, in the second quarter, the Company recorded a charge of $19 million solely for its future
legal defense costs for the Vioxx Litigation. Consequently, as of June 30, 2011, the aggregate
amount of the Vioxx Legal Defense Costs Reserve was approximately $58 million, which is solely for
future legal defense costs for the Vioxx Litigation. Some of the significant factors considered in
the review of the Vioxx Legal Defense Costs Reserve were as follows: the actual costs incurred by
the Company; the development of the Company’s legal defense strategy and structure in light of the
scope of the Vioxx Litigation, including the Settlement Agreement and the lawsuits that are
continuing; the number of cases being brought against the Company; the costs and outcomes of
completed trials and the most current information regarding anticipated timing, progression, and
related costs of pre-trial activities and trials in the Vioxx Litigation. The amount of the Vioxx
Legal Defense Costs Reserve as of June 30, 2011 represents the Company’s best estimate of the
minimum amount of defense costs to be incurred in connection with the remaining aspects of the
Vioxx Litigation; however, events such as additional trials in the Vioxx Litigation and other
events that could arise in the course of the Vioxx Litigation could affect the ultimate amount of
defense costs to be incurred by the Company.
The Company will continue to monitor its legal defense costs and review the adequacy of the
associated reserves and may determine to increase the Vioxx Legal Defense Costs Reserve at any time
in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Other Product Liability Litigation
Fosamax
As previously disclosed, Old Merck is a defendant in product liability lawsuits in the United
States involving Fosamax (the “Fosamax Litigation”). As of June 30, 2011, approximately 1,650
cases, which include approximately 2,050 plaintiff groups, had been filed and were pending against
Old Merck in either federal or state court, including one case which seeks class action
certification, as well as damages and/or medical monitoring. In approximately 1,115 of these
actions, plaintiffs allege, among other things, that they have suffered osteonecrosis of the jaw
(“ONJ”), generally subsequent to invasive dental procedures, such as tooth extraction or dental
implants and/or delayed healing, in association with the use of Fosamax. In addition, plaintiffs
in approximately 535 of these actions generally allege that they sustained femur fractures and/or
other bone injuries in association with the use of Fosamax.
Cases Alleging ONJ and/or Other Jaw Related Injuries
In August 2006, the JPML ordered that certain Fosamax product liability cases pending in
federal courts nationwide should be transferred and consolidated into one multidistrict litigation
(the “Fosamax MDL”) for coordinated pre-trial proceedings. The Fosamax MDL has been transferred to
Judge John Keenan in the U.S. District Court for the Southern District of New York. As a result of
the JPML order, approximately 910 of the cases are before Judge Keenan. Judge Keenan issued a Case
Management Order (and various amendments thereto) which set forth a schedule governing the
proceedings focused primarily upon resolving the class action certification
motions in 2007 and
completing fact discovery in an initial group of 25 cases by October 1, 2008. In January 2008,
briefing and argument on plaintiffs’ motions for certification of medical monitoring classes were
completed in 2007 after Judge Keenan issued an order denying the motions. Also in January 2008,
Judge Keenan issued a further order dismissing with prejudice all class claims asserted in the
first four class action lawsuits filed against Old Merck that
sought personal injury damages and/or medical monitoring relief on a class wide basis.
Daubert motions were filed in May 2009 and Judge Keenan conducted a Daubert hearing in July 2009.
In July 2009, Judge Keenan issued his ruling on the parties’ respective Daubert motions. The
ruling denied the Plaintiff Steering Committee’s motion and granted in part and denied in part Old
Merck’s motion. In the first Fosamax MDL trial, Boles v. Merck, the Fosamax MDL court declared a
mistrial because the eight person jury could not reach a unanimous verdict. The Boles case was
retried in June 2010 and resulted in a verdict in favor of the plaintiff in the amount of $8
million. Merck filed post-trial motions seeking judgment as a matter of law or, in the
alternative, a new trial. In October 2010, the court denied Merck’s post-trial motions but sua
sponte ordered a remittitur, reducing the verdict to $1.5 million. Plaintiff rejected the
remittitur ordered by the court and requested a new trial on damages. The Company has filed a
motion for interlocutory appeal, which included Merck’s motion
that the district court certify legal
issues for appeal to the U.S. Court of Appeals for the Second Circuit. On June 29, 2011, the
district court granted Merck’s motion and certified one legal
question for appeal, which is now pending.
In the next Fosamax MDL trial, Maley v. Merck, the jury in May 2010 returned a unanimous
verdict in Merck’s favor. In February 2010, Judge Keenan selected a new bellwether case, Judith
Graves v. Merck, to replace the Flemings bellwether case, which the Fosamax MDL court dismissed
when it granted summary judgment in favor of Old Merck. In November 2010, the Second Circuit
affirmed the court’s granting of summary judgment in favor of Old Merck in the Flemings case. In
Graves, the jury returned a unanimous verdict in favor of Old Merck in November 2010.
The next trials scheduled in the Fosamax MDL are Secrest v. Merck, which was scheduled to
begin on March 14, 2011, but has been continued until September 7, 2011, and Hester v. Merck, which
was scheduled to begin on May 9, 2011, but after Merck filed its motion for summary judgment,
plaintiff’s counsel dismissed Hester with prejudice. On April 27, 2011, Judge Keenan selected
Raber v. Merck as the case to replace Hester and set the trial for Raber to begin on November 7,
2011. In addition, Judge Keenan ordered on February 4, 2011 that there will be two further
bellwether trials conducted in the Fosamax MDL: Spano v. Merck is expected to be tried on February
27, 2012 and Jellema v. Merck is expected be tried on May 13, 2012.
Outside the Fosamax MDL, a trial in Florida, Anderson v. Merck, was scheduled to begin in June
2010 but the Florida state court postponed the trial date and a new date has been set for March 5,
2012. The trial ready date in Carballo v. Merck has been
continued from August 22, 2011 until January 9, 2012.
In addition, in July 2008, an application was made by the Atlantic County Superior Court of
New Jersey requesting that all of the Fosamax cases pending in New Jersey be considered for mass
tort designation and centralized management before one judge in New Jersey. In October 2008, the
New Jersey Supreme Court ordered that all pending and future actions filed in New Jersey arising
out of the use of Fosamax and seeking damages for existing dental and jaw-related injuries,
including ONJ, but not solely seeking medical monitoring, be designated as a mass tort for
centralized management purposes before Judge Carol E. Higbee in Atlantic County Superior Court. As of June
30, 2011, approximately 190 ONJ cases were pending against Old Merck in Atlantic County, New
Jersey. In July 2009, Judge Higbee entered a Case Management Order (and various amendments
thereto) setting forth a schedule that contemplates completing fact and expert discovery in an
initial group of cases to be reviewed for trial. On February 14, 2011, the jury in Rosenberg v.
Merck, the first trial in the New Jersey coordinated proceeding, returned a verdict in Merck’s
favor. A trial in the Rifkin v. Merck, Flores v. Merck and Sessner v. Merck cases is scheduled for
February 27, 2012.
In California, the parties are reviewing the claims of three plaintiffs in the Carrie Smith,
et al. v. Merck case and the claims in Pedrojetti v. Merck. The cases of one or more of these
plaintiffs is expected to be tried in March 2012.
Discovery is ongoing in the Fosamax MDL litigation, the New Jersey coordinated proceeding, and
the remaining jurisdictions where Fosamax cases are pending. The Company intends to defend against
these lawsuits.
Cases Alleging Femur Fractures and/or Other Bone Injuries
As of June 30, 2011, approximately 430 cases alleging femur fractures and/or other bone
injuries have been filed in New Jersey state court and are pending before Judge Higbee in Atlantic
County Superior Court. A Case
Management Order setting forth a schedule with respect to the
review of these cases is expected but has not yet been entered and no trial dates for any of the
New Jersey state femur fracture cases has been set.
On March 23, 2011, Merck submitted a Motion to Transfer to the JPML seeking to have all
federal cases alleging femur fractures and other bone injuries consolidated into one multidistrict
litigation for coordinated pre-trial proceedings. The Motion to Transfer was granted on May 23,
2011, and all federal cases involving allegations of
femur fracture or other bone injuries have been or will be transferred to the District of New
Jersey where the Fosamax MDL is sited. Judge Garrett Brown has been assigned to preside over this
second Fosamax MDL proceeding.
A petition was filed seeking to coordinate all femur fracture cases filed in California state
court before a single judge in Orange County, California. The petition was granted and Judge
Ronald L. Bauer will preside over the coordinated proceedings. No scheduling order has yet been
entered.
Additionally, there are three femur fracture cases pending in other state courts. One case is
pending in Massachusetts, one is pending in Florida, and one is pending in Oregon.
Discovery is ongoing in the federal and state courts where femur fracture cases are pending
and the Company intends to defend against these lawsuits.
NuvaRing
Beginning in May 2007, a number of complaints were filed in various jurisdictions asserting
claims against the Company’s subsidiaries Organon USA, Inc., Organon Pharmaceuticals USA, Inc.,
Organon International (collectively, “Organon”), and Schering-Plough arising from Organon’s
marketing and sale of NuvaRing, a combined hormonal contraceptive vaginal ring. The plaintiffs
contend that Organon and Schering-Plough failed to adequately warn of the alleged increased risk of
venous thromboembolism (“VTE”) posed by NuvaRing, and/or downplayed the risk of VTE. The plaintiffs
seek damages for injuries allegedly sustained from their product use, including some alleged
deaths, heart attacks and strokes. The majority of the cases are currently pending in a federal
multidistrict litigation (the “NuvaRing MDL”) venued in Missouri and in New Jersey state court.
As of June 30, 2011, there were approximately 815 NuvaRing cases. Of these cases, 690 are
pending in the NuvaRing MDL in the U.S. District Court for the Eastern District of Missouri before
Judge Rodney Sippel, and 122 are pending in consolidated discovery proceedings in the Bergen County
Superior Court of New Jersey before Judge Brian R. Martinotti. Four additional cases are pending
in various other state courts.
Pursuant to orders of Judge Sippel in the NuvaRing MDL, the parties selected 26 trial pool
cases which are the subject of fact discovery and this pool was recently narrowed to eight cases
from which the first trial cases will be selected. Pursuant to Judge Martinotti’s order, the
parties selected an additional 10 trial pool cases that are the subject of fact discovery in the
New Jersey consolidated proceedings. Based on a revised scheduling order entered in both
jurisdictions, fact discovery in the trial pool cases ended on June 24, 2011 and the Company
expects expert discovery to be completed by the end of February 2012. Based on the scheduling orders in
place in each jurisdiction, the Company anticipates that status conferences in each coordinated
proceeding will be held in March 2012 to determine a methodology for selecting the first cases to
be tried. The Company intends to defend against these lawsuits.
Governmental Proceedings
The DOJ has issued a subpoena requesting information related to the Company’s marketing and
selling activities with respect to Temodar, PegIntron and Intron A, from January 1, 2004 to the
present, in a federal health care investigation under criminal statutes. The Company is
cooperating with the DOJ’s investigation.
Vytorin/Zetia Litigation
As previously disclosed, in April 2008, an Old Merck shareholder filed a putative class action
lawsuit in federal court in the Eastern District of Pennsylvania alleging that Old Merck violated
the federal securities laws. This suit has since been withdrawn and re-filed in the District of
New Jersey and has been consolidated with another federal securities lawsuit under the caption In
re Merck & Co., Inc. Vytorin Securities Litigation. An amended consolidated complaint was filed in
October 2008, and names as defendants Old Merck; Merck/Schering-Plough Pharmaceuticals, LLC; and
certain of the Company’s current and former officers and directors. Specifically, the complaint
alleges that Old Merck delayed releasing unfavorable results of the ENHANCE clinical trial
regarding the efficacy of Vytorin and that Old Merck made false and misleading statements about
expected earnings, knowing that once the results of the Vytorin study were released, sales of
Vytorin would decline and Old Merck’s earnings would suffer. In December 2008, Old Merck and the
other defendants moved to dismiss this lawsuit on the grounds that the plaintiffs failed to state a
claim for which relief can be granted. In September 2009, the court issued an opinion and order
denying the defendants’ motion to dismiss this lawsuit and, in October 2009, Old Merck and the
other defendants filed an answer to the amended consolidated complaint. There is a similar
consolidated, putative class action securities lawsuit pending in the District of New Jersey, filed
by a Schering-Plough shareholder against Schering-Plough and its former Chairman, President and
Chief Executive Officer, Fred Hassan, under the caption In re Schering-Plough Corporation/ENHANCE
Securities Litigation. The amended consolidated complaint was filed in September 2008 and names as
defendants Schering-Plough; Merck/Schering-Plough Pharmaceuticals, LLC; certain of the Company’s
current and former officers and directors; and underwriters who participated in an August 2007
public offering of Schering-Plough’s common and preferred stock. In December 2008, Schering-Plough
and the other defendants filed motions to dismiss this lawsuit on the grounds that the plaintiffs
failed to state a claim for which relief can be granted. In September 2009, the court issued an
opinion and order denying the defendants’ motion to dismiss this lawsuit. The defendants filed an
answer to the consolidated amended complaint in November 2009.
As previously disclosed, in April 2008, a member of an Old Merck ERISA plan filed a putative
class action lawsuit against Old Merck and certain of the Company’s current and former officers and
directors alleging they breached their fiduciary duties under ERISA. Since that time, there have
been other similar ERISA lawsuits filed against Old Merck in the District of New Jersey, and all of
those lawsuits have been consolidated under the caption In re Merck & Co., Inc. Vytorin ERISA
Litigation. A consolidated amended complaint was filed in February 2009, and names as defendants
Old Merck and various current and former members of the Company’s Board of Directors. The
plaintiffs allege that the ERISA plans’ investment in Old Merck stock was imprudent because Old
Merck’s earnings are dependent on the commercial success of its cholesterol drug Vytorin and that
defendants knew or should have known that the results of a scientific study would cause the medical
community to turn to less expensive drugs for cholesterol management. In April 2009, Old Merck and
the other defendants moved to dismiss this lawsuit on the grounds that the plaintiffs failed to
state a claim for which relief can be granted. In September 2009, the court issued an opinion and
order denying the defendants’ motion to dismiss this lawsuit. In November 2009, the plaintiffs
moved to strike certain of the defendants’ affirmative defenses. That motion was denied in part
and granted in part in June 2010, and an amended answer was filed in July 2010.
There is a similar consolidated, putative class action ERISA lawsuit currently pending in the
District of New Jersey, filed by a member of a Schering-Plough ERISA plan against Schering-Plough
and certain of its current and former officers and directors, alleging they breached their
fiduciary duties under ERISA, and under the caption In re Schering-Plough Corp. ENHANCE ERISA
Litigation. The consolidated amended complaint was filed in October 2009 and names as defendants
Schering-Plough, various current and former members of Schering-Plough’s Board of Directors and
current and former members of committees of Schering-Plough’s Board of Directors. In November
2009, the Company and the other defendants filed a motion to dismiss this lawsuit on the grounds
that the plaintiffs failed to state a claim for which relief can be granted. The plaintiffs’
opposition to the motion to dismiss was filed in December 2009, and the motion was fully briefed in
January 2010. That motion was denied in June 2010. In September 2010, defendants filed an answer
to the amended complaint in this matter.
In November 2009, a stockholder of the Company filed a shareholder derivative lawsuit, In re
Local No. 38 International Brotherhood of Electrical Workers Pension Fund v. Clark (“Local No.
38”), in the District of New Jersey, on behalf of the nominal defendant, the Company, and all
shareholders of the Company, against the Company; certain of the Company’s officers, directors and
alleged insiders; and certain of the predecessor companies’ former officers, directors and alleged
insiders for alleged breaches of fiduciary duties, waste, unjust enrichment and gross
mismanagement. A similar shareholder derivative lawsuit, Cain v. Hassan, was filed by a
Schering-Plough stockholder and is currently pending in the District of New Jersey. An amended
complaint was filed in May 2008, by the Schering-Plough stockholder on behalf of the nominal
defendant, Schering-Plough, and all Schering-Plough shareholders. The lawsuit is against the
Company, Schering-Plough’s then-current Board of Directors, and certain of Schering-Plough’s
current and former officers, directors and alleged insiders. The plaintiffs in both Local No. 38
and Cain v. Hassan alleged that the defendants withheld the ENHANCE study results and made false
and misleading statements, thereby deceiving and causing harm to the Company and Schering-Plough,
respectively, and to the investing public, unjustly enriching insiders and wasting corporate
assets. The plaintiff in Local No. 38 voluntarily dismissed the suit without prejudice on April
29, 2011. The defendants in Cain v. Hassan filed a second amended complaint on June 3, 2011. The
defendants intend to move to dismiss the second amended complaint. In November 2010, a Company
shareholder filed a derivative lawsuit in state court in New Jersey. This case, captioned Rose v.
Hassan, asserts claims that are substantially identical to the claims alleged in Cain v. Hassan.
On July 7, 2011, the defendants in Rose moved to stay the case or to dismiss it without prejudice
in favor of the federal derivative action. That motion is fully briefed and a decision is pending.
Discovery in the lawsuits referred to in this section (collectively, the “ENHANCE Litigation”)
will be coordinated and has commenced. The Company believes that it has meritorious defenses to
the ENHANCE Litigation and intends to vigorously defend against these lawsuits. The Company is
unable to predict the outcome of these matters and at this time cannot reasonably estimate the
possible loss or range of loss with respect to the ENHANCE Litigation. Unfavorable outcomes
resulting from the ENHANCE Litigation could have a material adverse effect on the Company’s
financial position, liquidity and results of operations.
Insurance
The Company has Directors and Officers insurance coverage applicable to the Vytorin
shareholder lawsuits with stated upper limits of approximately $250 million. The Company has
Fiduciary and other insurance for the Vytorin ERISA lawsuits
with stated upper limits of approximately $265 million.
There are disputes with the insurers about the availability of some or all of the Company’s
insurance coverage for these claims and there are likely to be additional disputes. The amounts
actually recovered under the policies discussed in this paragraph may be less than the stated
limits.
Commercial Litigation
AWP Litigation and Investigations
As previously disclosed, the Company and/or certain of its subsidiaries remain defendants in
cases brought by various states and certain New York counties alleging manipulation by
pharmaceutical manufacturers of Average Wholesale Prices (“AWP”), which are sometimes used by
public and private payors in calculating provider reimbursement levels. The outcome of these
lawsuits could include substantial damages, the imposition of substantial fines and penalties and
injunctive or administrative remedies. In January 2010, the U.S. District Court for the District
of Massachusetts held that a unit of the Company and eight other drug makers overcharged New York
City and 42 New York counties for certain generic drugs. The court has reserved the issue of
damages and
any penalties for future proceedings. In a separate matter, in September 2010, a jury
in the U.S. District Court for the District of Massachusetts found the Company liable on the ground
that units of Schering-Plough caused Massachusetts to overpay pharmacists for prescriptions of
albuterol. The District Court held that
Massachusetts should be awarded approximately $13.8 million in treble damages and penalties,
together with prejudgment interest and attorney’s fees, but Massachusetts has moved to amend the
judgment to include substantially higher penalties. The Company intends to pursue a reversal of the verdict on appeal.
During 2011, the Company settled certain AWP cases brought by the states of Utah, South
Carolina, Alaska, Idaho, Kentucky, Pennsylvania, Mississippi, and Wisconsin. The Company and/or certain of its subsidiaries
continue to be defendants in cases brought by 13 states and the New York counties.
Centocor Distribution Agreement
In May 2009, Centocor, a wholly owned subsidiary of Johnson & Johnson, delivered to
Schering-Plough a notice initiating an arbitration proceeding to resolve whether, as a result of
the Merger, Centocor was permitted to terminate the Company’s rights to distribute and
commercialize Remicade and Simponi. On April 15, 2011, the Company announced that it had settled
the arbitration. Under the terms of the amended distribution agreement, Merck’s subsidiary,
Schering-Plough (Ireland), relinquished exclusive marketing rights for Remicade and Simponi to
Johnson & Johnson’s Janssen pharmaceutical companies in territories including Canada, Central and
South America, the Middle East, Africa and Asia Pacific (“Relinquished Territories”), effective
July 1, 2011. Merck retained exclusive marketing rights throughout Europe, Russia and Turkey
(“Retained Territories”). The Retained Territories represent approximately 70% of Merck’s 2010
revenue of $2.8 billion from Remicade and Simponi, while the Relinquished Territories
represent approximately 30%. In addition, all profit derived from Merck’s exclusive distribution
of the two products in the Retained Territories will be equally divided between Merck and Johnson &
Johnson, beginning July 1, 2011. Under the prior terms of the distribution agreement, the
contribution income (profit) split, which was at 58% to Merck and 42% to Centocor Ortho
Biotech Inc., would have declined for Merck and increased for Johnson & Johnson each year until
2014, when it would have been equally divided. Johnson & Johnson also received a one-time payment
from Merck of $500 million in April 2011.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug
Applications (“ANDAs”) with the FDA seeking to market generic forms of the Company’s products prior
to the expiration of relevant patents owned by the Company. To protect its patent rights the
Company may file patent infringement lawsuits against such generic companies. Certain products of
the Company (or marketed via agreements with other companies) currently involved in such patent
infringement litigation in the United States include: AzaSite, Cancidas, Integrilin, Nasonex,
Nexium, Noxafil, Propecia, Temodar, Vytorin and Zetia. Similar lawsuits defending the Company’s
patent rights may exist in other countries. The Company intends to vigorously defend its patents,
which it believes are valid, against infringement by generic companies attempting to market
products prior to the expiration of such patents. As with any litigation, there can be no
assurance of the outcomes, which, if adverse, could result in significantly shortened periods of
exclusivity for these products.
AzaSite — In May 2011, a patent infringement suit was filed in the United States against
Sandoz Inc. (“Sandoz”) in respect of Sandoz’s application to the FDA seeking pre-patent expiry
approval to market a generic version of AzaSite. The lawsuit automatically stays FDA approval of
Sandoz’s ANDA until October 2013 or until an adverse court decision, if any, whichever may occur
earlier.
Cancidas — In November 2009, a patent infringement lawsuit was filed in the United States
against Teva Parenteral Medicines, Inc. (“TPM”) in respect of TPM’s application to the FDA seeking
pre-patent expiry approval to sell a generic version of Cancidas. That lawsuit has been dismissed
with no rights granted to TPM. Also, in March 2010, a patent infringement lawsuit was filed in the
United States against Sandoz in respect of Sandoz’s application to the FDA seeking pre-patent
expiry approval to sell a generic version of Cancidas. In June 2011, Sandoz amended its challenge
to Merck’s Cancidas patents stating that it did not seek FDA approval any earlier than the expiry
of a patent which occurs on July 26, 2015, but Sandoz did maintain its challenge to a Cancidas
patent which expires on September 28, 2017. Therefore, the lawsuit will continue, however, the FDA
cannot approve Sandoz’s application any earlier than July 26, 2015.
Integrilin — In February 2009, a patent infringement lawsuit was filed (jointly with
Millennium Pharmaceuticals, Inc. (“Millennium”)) in the United States against TPM in respect of
TPM’s application to the FDA seeking approval to sell a generic version of Integrilin prior to the
expiry of the last to expire listed patent. As TPM
did not challenge certain patents that will not
expire until November 2014, FDA approval of the TPM application cannot occur any earlier than
November 2014, however, it could be later in the event of a favorable decision in the lawsuit for
the Company and Millennium.
Nasonex — In December 2009, a patent infringement suit was filed in the United States against
Apotex Corp. (“Apotex”) in respect of Apotex’s application to the FDA seeking pre-patent expiry
approval to market a generic version of Nasonex. The lawsuit automatically stays FDA approval of
Apotex’s ANDA until May 2012 or until an adverse court decision, if any, whichever may occur
earlier.
Nexium — In November 2005, a patent infringement lawsuit was filed (jointly with AstraZeneca)
in the United States against Ranbaxy Laboratories Ltd. (“Ranbaxy”) in respect of Ranbaxy’s
application to the FDA seeking pre-patent expiry approval to sell a generic version of Nexium. As
previously disclosed, AstraZeneca, Merck and Ranbaxy entered into a settlement agreement which
provided that Ranbaxy would be entitled to bring its generic esomeprazole product to market in the
United States on May 27, 2014. The Company and AstraZeneca each received a Civil Investigative
Demand (“CID”) from the Federal Trade Commission (“FTC”) in July 2008 regarding the settlement
agreement with Ranbaxy. The Company is cooperating with the FTC in responding to this CID. In
March 2006, a patent infringement lawsuit was filed (jointly with AstraZeneca) against IVAX
Pharmaceuticals, Inc. (“IVAX”) (later acquired by Teva Pharmaceuticals, Inc. (“Teva”)), in respect
of IVAX’s application to the FDA seeking pre-patent expiry approval to sell a generic version of
Nexium. In January 2010, AstraZeneca, Merck and Teva/IVAX entered into a settlement agreement
which provides that Teva/IVAX would be entitled to bring its generic esomeprazole product to market
in the United States on May 27, 2014. Patent infringement lawsuits have also been filed in the
United States against Dr. Reddy’s Laboratories (“Dr. Reddy’s”), Sandoz and Lupin Ltd. (“Lupin”) in
respect to their respective applications to the FDA seeking pre-patent expiry approval to sell
generic versions of Nexium. In January 2011, AstraZeneca, Merck and Dr. Reddy’s entered into a
settlement agreement which provides that Dr. Reddy’s would be entitled to bring its generic
esomeprazole product to market in the United States on May 27, 2014. In June 2011, AstraZeneca,
Merck and Sandoz entered into a settlement agreement which provides that Sandoz would be entitled
to bring its generic esomeprazole product to market in the United States on May 27, 2014. The
lawsuit against Lupin is ongoing with no trial dates presently scheduled. In February 2011, a
patent infringement lawsuit was filed (jointly with AstraZeneca) in the United States against Hamni
USA, Inc. (“Hamni”) in respect of Hamni’s application to the FDA seeking pre-patent expiry approval
to sell a generic version of Nexium. A patent infringement lawsuit was also filed (jointly with
AstraZeneca) in February 2010 in the United States against Sun Pharma Global Fze in respect of its
application to the FDA seeking pre-patent expiry approval to sell a generic version of Nexium IV.
Noxafil — In May 2011, a patent infringement suit was filed in the United States against
Sandoz in respect of Sandoz’s application to the FDA seeking pre-patent expiry approval to market a
generic version of Noxafil. The lawsuit automatically stays FDA approval of Sandoz’s ANDA until
September 2013 or until an adverse court decision, if any, whichever may occur earlier.
Propecia — In December 2010, a patent infringement lawsuit was filed in the United States
against Hetero Drugs Limited (“Hetero”) in respect of Hetero’s application to the FDA seeking
pre-patent expiry approval to sell a generic version of Propecia. In March 2011, the Company
settled this lawsuit with Hetero by agreeing to allow Hetero to sell a generic 1 mg finasteride
product beginning on July 1, 2013.
Temodar — In July 2007, a patent infringement action was filed (jointly with Cancer Research
Technologies, Limited (“CRT”)) in the United States against Barr Laboratories (“Barr”) (later
acquired by Teva) in respect of Barr’s application to the FDA seeking pre-patent expiry approval to
sell a generic version of Temodar. In January 2010, the court issued a decision finding the CRT
patent unenforceable on grounds of prosecution laches and inequitable conduct. In November 2010,
the appeals court issued a decision reversing the trial court’s finding. In December 2010, Barr
filed a petition seeking a rehearing en banc of the appeal, which petition was denied. In June
2011, Barr filed a petition for review by the United States Supreme Court. By virtue of an
agreement that Barr not launch a product during the appeal process, the Company has agreed that
Barr can launch a product in August 2013.
In September 2010, a patent infringement lawsuit was filed (jointly with CRT) in the United
States against Sun Pharmaceutical Industries Inc. (“Sun”) in respect of Sun’s application to the
FDA seeking pre-patent expiry approval to sell a generic version of Temodar. The lawsuit
automatically stays FDA approval of Sun’s ANDA until February 2013 or until an adverse court
decision, if any, whichever may occur earlier. In November 2010, a patent infringement lawsuit was
filed (jointly with CRT) in the United States against Accord HealthCare Inc. (“Accord”) in respect
of its application to the FDA seeking pre-patent expiry approval to sell a generic version of
Temodar. The Company, CRT and Accord have entered an agreement to stay the lawsuit pending the
outcome of the appeal en banc process in the Barr lawsuit.
Vytorin — In December 2009, a patent infringement lawsuit was filed in the United States
against Mylan Pharmaceuticals, Inc. (“Mylan”) in respect of Mylan’s application to the FDA seeking
pre-patent expiry approval to sell a generic version of Vytorin. The lawsuit automatically stays
FDA approval of Mylan’s application until May 2012 or until an adverse court decision, if any,
whichever may occur earlier. A trial against Mylan jointly in respect of Zetia and Vytorin is
scheduled to begin on December 5, 2011. In February 2010, a patent infringement lawsuit was filed
in the United States against Teva in respect of Teva’s application to the FDA seeking pre-patent
expiry approval to sell a generic version of Vytorin. In July 2011, the patent infringement
lawsuit was dismissed and Teva agreed not to sell generic versions of Zetia or Vytorin until the
Company’s exclusivity rights expire on April 25, 2017, except in certain circumstances. In August
2010, a patent infringement lawsuit was filed in the United States
against Impax Laboratories Inc. (“Impax”) in respect of Impax’s application to the FDA seeking
pre-patent expiry approval to sell a generic version of Vytorin. An agreement was reached with
Impax to stay the lawsuit pending the outcome of the lawsuit with Mylan.
Zetia — In March 2007, a patent infringement lawsuit was filed in the United States against
Glenmark Pharmaceuticals Inc., USA and its parent corporation (collectively, “Glenmark”) in respect
of Glenmark’s application to the FDA seeking pre-patent expiry approval to sell a generic version
of Zetia. In May 2010, Glenmark agreed to a settlement by virtue of which Glenmark will be
permitted to launch its generic product in the United States on December 12, 2016, subject to
receiving final FDA approval. In June 2010, a patent infringement lawsuit was filed in the United
States against Mylan in respect of Mylan’s application to the FDA seeking pre-patent expiry
approval to sell a generic version of Zetia. The lawsuit automatically stays FDA approval of
Mylan’s application until December 2012 or until an adverse court decision, if any, whichever may
occur earlier. A trial against Mylan jointly in respect of Zetia and Vytorin is scheduled to begin
on December 5, 2011. In September 2010, a patent infringement lawsuit was filed in the United
States against Teva in respect of Teva’s application to the FDA seeking pre-patent expiry approval
to sell a generic version of Zetia. In July 2011, the patent infringement lawsuit was dismissed
without any rights granted to Teva.
NuvaRing — In February 2011, a patent infringement suit was brought against Merck in the
International Trade Commission by Femina Pharma Incorporated (“Femina”) in respect of the product
NuvaRing. The complaint alleges that NuvaRing infringes a patent owned by Femina. The lawsuit
seeks an exclusion order against the importation of NuvaRing into the United States. Trial in the
case is scheduled to begin on October 3, 2011.
Environmental Matters
As previously disclosed, approximately 2,200 plaintiffs have filed an amended complaint
against Old Merck and 12 other defendants in U.S. District Court, Eastern District of California
asserting claims under the Clean Water Act, the Resource Conservation and Recovery Act, as well as
negligence and nuisance. The suit seeks damages for personal injury, diminution of property value,
medical monitoring and other alleged real and personal property damage associated with groundwater,
surface water and soil contamination found at the site of a former Old Merck subsidiary in Merced,
California. Certain of the other defendants in this suit have settled with plaintiffs regarding
some or all aspects of plaintiffs’ claims. This lawsuit is proceeding in a phased manner. A jury
trial commenced in February 2011 during which a jury was asked to make certain factual findings
regarding whether contamination moved off-site to any areas where plaintiffs could have been
exposed to such contamination and, if so, when, where and in what amounts. Defendants in this
“Phase 1” trial include Old Merck and three of the other original 12 defendants. On March 31,
2011, the Phase 1 jury returned a mixed verdict, finding in favor of Old Merck and the other
defendants as to some, but not all, of plaintiffs’ claims. Specifically, the jury found that
contamination from the site did not enter or affect plaintiffs’ municipal water supply wells or any
private domestic wells. The jury found, however, that plaintiffs could have been exposed to
contamination via air emissions prior to 1994, as well as via surface water in the form of storm
drainage channeled into an adjacent irrigation canal, including during a flood in April 2006. Old
Merck has filed motions requesting that the court set aside those portions of the jury’s verdict
that are adverse to Old Merck on the basis that those portions of the verdict are unsupported by
the evidence and contrary to established legal principles. If necessary, Old Merck will seek to
appeal, prior to commencement of any later phases of the litigation, those portions of the jury’s
verdict adverse to Old Merck that are not set aside by the trial court. In the event the Phase 1
jury’s findings in favor of plaintiffs are not set aside by the trial court or on appeal, it is
anticipated that later phases of the litigation would be required to address issues related to
liability, causation and damages related to specific plaintiffs.
In the second quarter of 2011, the DOJ and the U.S. Environmental Protection Agency (the “EPA”)
notified the Company that they are pursuing civil penalties against Merck in excess of $2 million
for alleged violations of air, water and waste regulations resulting from the EPA’s multi-media
inspections of Merck’s West Point and Riverside, Pennsylvania facilities in 2006 and Merck’s
subsequent information submissions to the EPA. The Company believes
that it has meritorious defenses to these allegations.
The EPA and Merck have entered into a consent decree under which Merck paid a $260,000 fine to
resolve alleged environmental violations at Merck’s Las Piedras Puerto Rico facility. The alleged
violations arose from an EPA air inspection conducted in July 2008 and were primarily based on the
site’s leak detection and repair program.
Other Litigation
There are various other legal proceedings, principally product liability and intellectual
property suits, involving the Company that are pending. While it is not feasible to predict the
outcome of such proceedings or
the proceedings discussed in this Note for which a separate
assessment is not provided, in the opinion of the Company, the amount or range of reasonably possible loss associated with the
resolution of such proceedings,
either individually or in the aggregate, is not material.
|
Taxes on Income
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Taxes on Income [Abstract] | |
Taxes on Income |
14. Taxes on Income
The effective tax rates of (22.8%) for the
second quarter of 2011 and 8.1% for the first six
months of 2011 reflect a net favorable impact relating to the
settlement of Old Merck’s 2002-2005 federal income tax audit as
discussed below, as
well as a $230 million net favorable impact of
certain foreign and state tax rate changes that resulted in a reduction of
deferred tax liabilities on intangibles established in purchase accounting. The tax rates also
reflect the impacts of purchase accounting adjustments and restructuring costs, partially offset by
the beneficial impact of foreign earnings. In addition, the effective tax rate for the first six
months of 2011 reflects the impacts of the $500 million charge related to the resolution of the
arbitration proceeding with Johnson & Johnson. The effective tax rates of 37.1% for the second
quarter of 2010 and 40.2% for the first six months of 2010, as compared with the statutory rate of
35%, reflect the unfavorable impact of purchase accounting charges, AstraZeneca’s asset option
exercise and restructuring charges, largely offset by the beneficial impact of foreign earnings.
In addition, the effective tax rate for the first six months of 2010 reflects the unfavorable
impact of a $147 million charge associated with a change in tax law that requires taxation of the
prescription drug subsidy of the Company’s retiree health benefit plans which was enacted in the
first quarter of 2010 as part of U.S. health care reform legislation.
The Company and Old Merck are both under examination by numerous tax authorities in various
jurisdictions globally.
The Company anticipates that its liability for unrecognized tax benefits at December 31, 2010
will be reduced by approximately $1.3 billion during 2011, as a result of various audit closures,
including the Internal Revenue Service (“IRS”) settlement discussed below, other settlements or the expiration of the statute of
limitations. The ultimate finalization of the Company’s examinations with relevant taxing
authorities can include formal administrative and legal proceedings, which could have a significant
impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its
reserves for uncertain tax positions are adequate to cover any risks or exposures.
In April 2011, the IRS concluded its examination of Old Merck’s 2002-2005 federal income tax
returns and as a result the Company was required to make net payments of approximately $465
million. The Company’s unrecognized tax benefits for the years under examination exceeded the
adjustments related to this examination period and therefore the Company recorded a net $700
million tax provision benefit in the second quarter of 2011. This net benefit reflects the
decrease of unrecognized tax benefits for the years under examination partially offset by increases
to the unrecognized tax benefits for years subsequent to the examination period as a result of this
settlement. The Company disagrees with the IRS treatment of one issue raised during this
examination and is appealing the matter through the IRS administrative process.
As previously disclosed, the Canada Revenue Agency (“CRA”) has proposed adjustments for 1999
and 2000 relating to intercompany pricing matters and, in July 2011, the CRA issued assessments for
other miscellaneous audit issues for tax years 2001-2004. These adjustments would increase
Canadian tax due by
approximately $340 million (U.S. dollars) plus approximately $375 million (U.S. dollars) of
interest through June 30, 2011. The Company disagrees with the positions taken by the CRA and
believes they are without merit. The Company continues to contest the assessments through the CRA
appeals process. The CRA is expected to prepare similar adjustments for later years. Management
believes that resolution of these matters will not have a material effect on the Company’s
financial position or liquidity.
In October 2001, IRS auditors asserted that two interest rate swaps that Schering-Plough
entered into with an unrelated party should be re-characterized as loans from affiliated companies,
resulting in additional tax liability for the 1991 and 1992 tax years. In September 2004,
Schering-Plough made payments to the IRS in the amount of $194 million for income taxes and $279
million for interest. The Company’s tax reserves were adequate to cover these payments.
Schering-Plough filed refund claims for the taxes and interest with the IRS in December 2004.
Following the IRS’s denial of Schering-Plough’s claims for a refund, Schering-Plough filed suit in
May 2005 in the U.S. District Court for the District of New Jersey for refund of the full amount of
taxes and interest. A decision in favor of the government was announced in August 2009. The
Company’s appeal of the decision was denied by the U.S. Court of Appeals for the Third Circuit in
June 2011. The Company is petitioning the court for a rehearing.
In 2010, the IRS finalized its examination of Schering-Plough’s
2003-2006 tax years. In this audit cycle, the Company reached an agreement with the IRS on an
adjustment to income related to intercompany pricing matters. This income adjustment mostly
reduced net operating losses (“NOLs”) and other tax credit carryforwards. Additionally, the
Company is seeking resolution of one issue raised during this examination through the IRS
administrative appeals process. The Company’s reserves for uncertain tax positions were adequate
to cover all adjustments related to this examination period. The IRS began its examination of the
2007-2009 tax years for the Company in 2010.
|
Equity
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity |
10. Equity
In connection with the 1998 restructuring of Astra Merck Inc., the Company assumed $2.4
billion par value preferred stock with a dividend rate of 5% per annum, which is carried by KBI and
included in Noncontrolling interests on the Consolidated Balance Sheet. If AstraZeneca exercises
the Shares Option (see Note 8), this preferred stock obligation will be settled.
The accumulated balances related to each component of other comprehensive income (loss), net
of taxes, were as follows:
Comprehensive income (loss) was $2.4 billion and $(335) million for the three months ended
June 30, 2011 and 2010, respectively, and was $3.5 billion and $(841) million for the six months
ended June 30, 2011 and 2010, respectively.
Included
in the cumulative translation adjustment are pretax (losses) gains of $(178) million
and $462 million for the first six months of 2011 and 2010, respectively, from euro-denominated
notes which have been designated as, and are effective as, economic hedges of the net investment in
a foreign operation. Also included in cumulative translation adjustment are pretax gains (losses)
of approximately $340 million and $(2.1) billion for the first six months of 2011 and 2010,
respectively, relating to the translation impacts of intangible assets recorded in conjunction with
the Merger.
|
Segment Reporting (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues and profits for segments |
Revenues and profits for these segments are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sales of the Company's products |
Sales of the Company’s products were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of segment profits to Income Before Taxes |
A reconciliation of segment profits to Income before taxes is as follows:
|
Joint Ventures and Other Equity Method Affiliates
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Joint Ventures and Other Equity Method Affiliates [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Joint Ventures and Other Equity Method Affiliates |
8. Joint Ventures and Other Equity Method Affiliates
Equity income from affiliates reflects the performance of the Company’s joint ventures and
other equity method affiliates and was comprised of the following:
AstraZeneca LP
In 1998, Old Merck and Astra completed the restructuring of the ownership and operations of
their existing joint venture whereby Old Merck acquired Astra’s interest in KBI Inc. (“KBI”) and
contributed KBI’s operating assets to a new U.S. limited partnership, Astra Pharmaceuticals L.P.
(the “Partnership”), in exchange for a 1% limited partner interest. Astra contributed the net
assets of its wholly owned subsidiary, Astra USA, Inc., to the Partnership in exchange for a 99%
general partner interest. The Partnership, renamed AstraZeneca LP (“AZLP”) upon Astra’s 1999 merger
with Zeneca Group Plc (the “AstraZeneca merger”), became the exclusive distributor of the products
for which KBI retained rights.
In connection with the 1998 restructuring, Astra purchased an option (the “Asset Option”) for
a payment of $443 million, which was recorded as deferred income, to buy Old Merck’s interest in
the KBI products, excluding the gastrointestinal medicines Nexium and Prilosec (the “Non-PPI
Products”). In April 2010, AstraZeneca exercised the Asset Option. Merck received $647 million
from AstraZeneca, representing the net present value as of March 31, 2008 of projected future
pretax revenue to be received by Old Merck from the Non-PPI Products, which was recorded as a
reduction to the Company’s investment in AZLP. The Company recognized the $443 million of deferred
income in the second quarter of 2010 as a component of Other (income) expense, net. In addition,
in 1998, Old Merck granted Astra an option (the “Shares Option”) to buy Old Merck’s common stock
interest in KBI and, therefore, Old Merck’s interest in Nexium and Prilosec, exercisable in 2012.
The exercise price for the Shares Option will be based on the net present value of estimated future
net sales of Nexium and Prilosec as determined at the time of exercise, subject to certain true-up
mechanisms. The Company believes that it is likely that AstraZeneca will exercise the Shares
Option.
Summarized financial information for AZLP is as follows:
|
Pension and Other Postretirement Benefit Plans (Details) (USD $)
In Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Pension Plans, Defined Benefit [Member]
|
||||
Components of net cost of defined benefit plans | ||||
Service cost | $ 151 | $ 147 | $ 303 | $ 301 |
Interest cost | 180 | 172 | 359 | 349 |
Expected return on plan assets | (242) | (215) | (485) | (432) |
Net amortization | 46 | 43 | 91 | 88 |
Termination benefits | 7 | 9 | 17 | 28 |
Curtailments | (6) | (1) | (10) | (37) |
Settlements | 0 | (6) | (1) | (7) |
Net cost | 136 | 149 | 274 | 290 |
Other Postretirement Benefit Plans, Defined Benefit [Member]
|
||||
Components of net cost of defined benefit plans | ||||
Service cost | 28 | 28 | 56 | 54 |
Interest cost | 35 | 36 | 71 | 74 |
Expected return on plan assets | (36) | (33) | (71) | (65) |
Net amortization | (6) | 2 | (9) | 4 |
Termination benefits | 4 | 7 | 6 | 27 |
Curtailments | 0 | (2) | 1 | (2) |
Net cost | $ 25 | $ 38 | $ 54 | $ 92 |
Basis of Presentation
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Basis of presentation [Abstract] | |
Basis of Presentation |
1. Basis of Presentation
The accompanying unaudited interim consolidated financial statements have been prepared
pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information
and disclosures required by accounting principles generally accepted in the United States for
complete consolidated financial statements are not included herein.
These interim statements should
be read in conjunction with the audited financial statements and notes thereto included in Merck &
Co., Inc.’s Form 10-K filed on February 28, 2011.
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation
(“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger,
Schering-Plough acquired all of the shares of Old Merck, which became a wholly owned subsidiary of
Schering-Plough and was renamed Merck Sharp & Dohme Corp. Schering-Plough continued as the
surviving public company and was renamed Merck & Co., Inc. (“New Merck” or the “Company”).
However, for accounting purposes only, the Merger was treated as an acquisition with Old Merck
considered the accounting acquirer. References in these financial statements to “Merck” for
periods prior to the Merger refer to Old Merck and for periods after the completion of the Merger
to New Merck.
The results of operations of any interim period are not necessarily indicative of the results
of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair
presentation of these interim statements have been included and are of a normal and recurring
nature.
Certain reclassifications have been made to prior year amounts to conform to the current year
presentation.
Recently Adopted Accounting Standards
In October 2009, the Financial Accounting Standards Board (“FASB”) issued new guidance for
revenue recognition with multiple deliverables. The Company adopted this guidance prospectively
for revenue arrangements entered into or materially modified on or after January 1, 2011. This
guidance eliminates the residual method under the current guidance and replaces it with the
“relative selling price” method when allocating revenue in a multiple deliverable arrangement. The
selling price for each deliverable shall be determined using vendor specific objective evidence of
selling price, if it exists, otherwise third-party evidence of selling price shall be used. If
neither exists for a deliverable, the vendor shall use its best estimate of the selling price for
that deliverable. The effect of adoption on the Company’s financial position and results of
operations was not material.
Recently Issued Accounting Standards
In June 2011, the FASB issued amended guidance on the presentation of comprehensive income in
financial statements. This amendment provides companies the option to present the components of
net income and other comprehensive income either as one continuous statement of comprehensive
income or as two separate but consecutive statements. It eliminates the option to present
components of other comprehensive income as part of the statement of changes in stockholders’
equity. The provisions of this new guidance are effective for interim and annual periods beginning
in 2012. The adoption of this new guidance will not impact the Company’s financial position,
results of operations or cash flows.
|
Collaborative Arrangements
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Collaborative Arrangements [Abstract] | |
Collaborative Arrangements |
4. Collaborative Arrangements
The Company continues its strategy of establishing external alliances to complement its
substantial internal research capabilities, including research collaborations, licensing
preclinical and clinical compounds and technology platforms to drive both near- and long-term
growth. The Company supplements its internal research with a licensing and external alliance
strategy focused on the entire spectrum of collaborations from early research to late-stage
compounds, as well as new technologies across a broad range of therapeutic areas. These
arrangements often include upfront payments and royalty or profit share payments, contingent upon
the occurrence of certain future events linked to the success of the asset in development, as well
as expense reimbursements or payments to the third party.
Cozaar/Hyzaar
In 1989, Old Merck and E.I. duPont de Nemours and Company (“DuPont”) agreed to form a
long-term research and marketing collaboration to develop a class of therapeutic agents for high
blood pressure and heart disease, discovered by DuPont, called angiotensin II receptor antagonists,
which include Cozaar and Hyzaar. In return, Old Merck provided DuPont marketing rights in the
United States and Canada to its prescription medicines, Sinemet and Sinemet CR (the Company has
since regained global marketing rights to Sinemet and Sinemet CR). Pursuant to a 1994 agreement
with DuPont, the Company has an exclusive licensing agreement to market Cozaar and Hyzaar, which
are both registered trademarks of DuPont, in return for royalties and profit share payments to
DuPont. The patents that provided market exclusivity in the United States for Cozaar and Hyzaar
expired in April 2010. In addition, Cozaar and Hyzaar lost patent protection in a number of major
European markets in March 2010.
Remicade/Simponi
In 1998, a subsidiary of Schering-Plough entered into a licensing agreement with Centocor
Ortho Biotech Inc. (“Centocor”), a Johnson & Johnson company, to market Remicade, which is
prescribed for the treatment of inflammatory diseases. In 2005, Schering-Plough’s subsidiary
exercised an option under its contract with Centocor for license rights to develop and
commercialize Simponi (golimumab), a fully human monoclonal antibody. The Company had exclusive
marketing rights to both products outside the United States, Japan and certain other Asian markets.
In December 2007, Schering-Plough and Centocor revised their distribution agreement regarding the
development, commercialization and distribution of both Remicade and Simponi, extending the
Company’s rights to exclusively market Remicade to match the duration of the Company’s exclusive
marketing rights for Simponi. In addition, Schering-Plough and Centocor agreed to share certain
development costs relating to Simponi’s auto-injector delivery system. On October 6, 2009, the
European Commission approved Simponi as a treatment for rheumatoid arthritis and other immune
system disorders in two presentations — a novel auto-injector and a prefilled syringe. As a
result, the Company’s marketing rights for both products extend for 15 years from the first
commercial sale of Simponi in the European Union (“EU”) following the receipt of pricing and
reimbursement approval within the EU. In April 2011, Merck and Johnson & Johnson reached agreement
to amend the distribution rights to Remicade and Simponi. Under the terms of the amended
distribution agreement, Merck relinquished exclusive marketing rights for Remicade and Simponi to
Johnson & Johnson in territories including Canada, Central and South America, the Middle East,
Africa and Asia Pacific effective July 1, 2011. Merck retained exclusive marketing rights
throughout Europe, Russia and Turkey (“Retained Territories”). In addition, beginning July 1,
2011, all profit derived from Merck’s exclusive distribution of the two products in the Retained
Territories is being equally divided between Merck and Johnson & Johnson. Under the prior terms of
the distribution agreement, the contribution income (profit) split, which was at 58% to Merck and
42% percent to Johnson & Johnson, would have declined for Merck and increased for Johnson & Johnson
each year until 2014, when it would have been equally divided. Johnson & Johnson also received a
one-time payment of $500 million in April 2011, which the
Company recorded as a charge to Other
(income) expense, net in the first quarter of 2011.
|
Financial Instruments (Details 2) (USD $)
In Millions |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Fair value of derivatives segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments | ||
Fair Value of Derivative, Asset | $ 557 | $ 628 |
Fair Value of Derivative, Liability | 68 | 61 |
Derivatives Not Designated as Hedging Instruments | ||
U.S. Dollar Notional | $ 23,583 | $ 20,446 |
Earnings Per Share (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculations of earnings per share under the two-class method |
The calculations of earnings per share under the two-class method are as follows:
|
Financial Instruments
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments |
5. Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements
on its earnings, cash flows and fair values of assets and liabilities through operational means and
through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed
to changes in foreign exchange rates. The objectives and accounting related to the Company’s
foreign currency risk management program, as well as its interest rate risk management activities
are discussed below.
Foreign Currency Risk Management
A significant portion of the Company’s revenues are denominated in foreign currencies. The
Company has established revenue hedging and balance sheet risk management programs to protect
against volatility of future foreign currency cash flows and changes in fair value caused by
volatility in foreign exchange rates.
The objective of the revenue hedging program is to reduce the potential for longer-term
unfavorable changes in foreign exchange to decrease the U.S. dollar value of future cash flows
derived from foreign currency denominated sales, primarily the euro and Japanese yen. To achieve
this objective, the Company will partially hedge forecasted foreign currency denominated
third-party and intercompany distributor entity sales that are expected to occur over its planning
cycle, typically no more than three years into the future. The Company will layer in hedges over
time, increasing the portion of third-party and intercompany distributor entity sales hedged as it
gets closer to the expected date of the forecasted foreign currency denominated sales, such that it
is probable the hedged transaction will occur. The portion of sales hedged is based on assessments
of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate
volatilities and correlations, and the cost of hedging instruments. The hedged anticipated sales
are a specified component of a portfolio of similarly denominated foreign currency-based sales
transactions, each of which responds to the hedged risk in the same manner. The Company manages
its anticipated transaction exposure principally with purchased local currency put options, which
provide the Company with a right, but not an obligation, to sell foreign currencies in the future
at a predetermined price. If the U.S. dollar strengthens relative to the currency of the hedged
anticipated sales, total changes in the options’ cash flows offset the decline in the expected
future U.S. dollar cash flows of the hedged foreign currency sales. Conversely, if the U.S. dollar
weakens, the options’ value reduces to zero, but the Company benefits from the increase in the
value of the anticipated foreign currency cash flows.
In connection with the Company’s revenue hedging program, a purchased collar option strategy
may be utilized. With a purchased collar option strategy, the Company writes a local currency call
option and purchases a local currency put option. As compared to a purchased put option strategy
alone, a purchased collar strategy reduces the upfront costs associated with purchasing puts
through the collection of premium by writing call options. If the U.S. dollar weakens relative to
the currency of the hedged anticipated sales, the purchased put option value of the collar strategy
reduces to zero, but the Company benefit from the increase in the value of its anticipated foreign
currency cash flows would be capped at the strike level of the written call. If the U.S. dollar
strengthens relative to the currency of the hedged anticipated sales, the written call option value
of the collar strategy reduces to zero and the changes in the purchased put cash flows of the
collar strategy would offset the decline in the expected future U.S. dollar cash flows of the
hedged foreign currency sales.
The Company may also utilize forward contracts in its revenue hedging program. If the U.S.
dollar strengthens relative to the currency of the hedged anticipated sales, the increase in the
fair value of the forward contracts offsets the decrease in the expected future U.S. dollar cash
flows of the hedged foreign currency sales. Conversely, if the U.S. dollar weakens, the decrease
in the fair value of the forward contracts offsets the increase in the value of the anticipated
foreign currency cash flows.
The fair values of these derivative contracts are recorded as either assets (gain positions)
or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of
derivative contracts are recorded each period in either current earnings or Other comprehensive
income (“OCI”), depending on whether the
derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges,
the effective portion of the unrealized gains or losses on these contracts is recorded in
Accumulated other comprehensive income (“AOCI”) and reclassified into Sales when the hedged
anticipated revenue is recognized. The hedge relationship is highly effective and hedge
ineffectiveness has been de minimis. For those derivatives which are not designated as cash flow
hedges, unrealized gains or losses are recorded to Sales each period. The cash flows from these
contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The
Company does not enter into derivatives for trading or speculative purposes.
The primary objective of the balance sheet risk management program is to mitigate the exposure
of foreign currency denominated net monetary assets of foreign subsidiaries where the U.S. dollar
is the functional currency from the effects of volatility in foreign exchange that might occur
prior to their conversion to U.S. dollars. In these instances, Merck principally utilizes forward
exchange contracts, which enable the Company to buy and sell foreign currencies in the future at
fixed exchange rates and economically offset the consequences of changes in foreign exchange from
the monetary assets. Merck routinely enters into contracts to offset the effects of exchange on
exposures denominated in developed country currencies, primarily the euro and Japanese yen. For
exposures in developing country currencies, the Company will enter into forward contracts to
partially offset the effects of exchange on exposures when it is deemed economical to do so based
on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the
exchange rate and the cost of the hedging instrument. The Company will also minimize the effect of
exchange on monetary assets and liabilities by managing operating activities and net asset
positions at the local level.
Foreign currency denominated monetary assets and liabilities of foreign subsidiaries where the
U.S. dollar is the functional currency are remeasured at spot rates in effect on the balance sheet
date with the effects of changes in spot rates reported in Other (income) expense, net. The
forward contracts are not designated as hedges and are marked to market through Other (income)
expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes
in the value of the remeasured assets and liabilities attributable to changes in foreign currency
exchange rates, except to the extent of the spot-forward differences. These differences are not
significant due to the short-term nature of the contracts, which typically have average maturities
at inception of less than one year.
When applicable, the Company uses forward contracts to hedge the changes in fair value of
certain foreign currency denominated available-for-sale securities attributable to fluctuations in
foreign currency exchange rates. These derivative contracts are designated as fair value hedges.
Accordingly, changes in the fair value of the hedged securities due to fluctuations in spot rates
are recorded in Other (income) expense, net, and are offset by the fair value changes in the
forward contracts attributable to spot rate fluctuations. Changes in the contracts’ fair value due
to spot-forward differences are excluded from the designated hedge relationship and recognized in
Other (income) expense, net. These amounts, as well as hedge ineffectiveness, were not
significant. The cash flows from these contracts are reported as operating activities in the
Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s
senior unsecured euro-denominated notes have been designated as, and are effective as, economic
hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction
gains or losses on the euro-denominated debt instruments are included in foreign currency
translation adjustment within OCI.
The Company also uses forward exchange contracts to hedge its net investment in foreign
operations against adverse movements in exchange rates. The forward contracts are designated as
hedges of the net investment in a foreign operation. The Company hedges a portion of the net
investment in certain of its foreign operations and measures ineffectiveness based upon changes in
spot foreign exchange rates. The effective portion of the unrealized gains or losses on these
contracts is recorded in foreign currency translation adjustment
within OCI, and remains in AOCI
until either the sale or complete or substantially complete liquidation of the subsidiary. The
cash flows from these contracts are reported as investing activities in the Consolidated Statement
of Cash Flows.
Interest Rate Risk Management
In June 2011, the Company terminated nine interest rate swap contracts with a total notional
amount of $3.5 billion. These swaps effectively converted $3.5 billion of its fixed-rate notes,
with maturity dates varying from March 2015 to June 2019, to floating rate instruments. As a
result of the swap terminations, the Company received $175 million in cash, which included $36
million in accrued interest. The corresponding $139 million basis
adjustment of the debt associated with the terminated swap contracts
was deferred and is being
amortized as a reduction of interest expense over the respective term of the notes. The cash flows
from these contracts are reported as operating activities in the Consolidated Statement of Cash
Flows.
At June 30, 2011, the Company was a party to 13 pay-floating, receive-fixed interest rate swap
contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match
the amount of the hedged fixed-rate notes. There are two swaps maturing in 2011 with notional
amounts of $125 million each that effectively convert the Company’s $250 million, 5.125% fixed-rate
notes due 2011 to floating rate instruments. There are five swaps maturing in 2015 with notional
amounts of $150 million each that effectively convert $750 million of the Company’s 4.0% fixed-rate
notes due 2015 to floating rate instruments. There are six swaps maturing in 2016, two of which
have notional amounts of $175 million each, and four of which have notional amounts of $125 million
each, that effectively convert the Company’s $850 million, 2.25% fixed-rate notes due 2016 to
floating rate instruments. The interest rate swap contracts are designated hedges of the fair
value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate
(“LIBOR”) swap rate. The fair value changes in the notes attributable to changes in the benchmark
interest rate are recorded in interest expense and offset by the fair value changes in the swap
contracts. The cash flows from these contracts are reported as operating activities in the
Consolidated Statement of Cash Flows.
Presented in the table below is the fair value of derivatives segregated between those
derivatives that are designated as hedging instruments and those that are not designated as hedging
instruments:
The table below provides information on the location and pretax gain or loss amounts for
derivatives that are: (i) designated in a fair value hedging relationship, (ii) designated in a
cash flow hedging relationship, (iii) designated in a foreign currency hedging relationship (net
investment hedge) and (iv) not designated in a hedging relationship:
At June 30, 2011, the Company estimates $107 million of pretax net unrealized losses on
derivatives maturing within the next 12 months that hedge foreign currency denominated sales over
that same period will be reclassified from AOCI to Sales. The amount ultimately reclassified to
Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately
determined by actual exchange rates at maturity.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants on the measurement date. Entities
are required to use a fair value hierarchy which maximizes the use of observable inputs and
minimizes the use of unobservable inputs when measuring fair value. There are three levels of
inputs that may be used to measure fair value:
Level 1 - Quoted prices in active markets for identical assets or liabilities. The Company’s
Level 1 assets include equity securities that are traded in an active exchange market.
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar
assets or liabilities, or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities. The Company’s Level 2
assets and liabilities primarily include debt securities with quoted prices that are traded less
frequently than exchange-traded instruments, corporate notes and bonds, U.S. and foreign government
and agency securities, certain mortgage-backed and asset-backed securities, municipal securities,
commercial paper and derivative contracts whose values are determined using pricing models with
inputs that are observable in the market or can be derived principally from or corroborated by
observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are
financial instruments whose values are determined using pricing models, discounted cash flow
methodologies, or similar techniques, as well as instruments for which the determination of fair
value requires significant judgment or estimation. The Company’s Level 3 assets included certain
mortgage-backed securities with limited market activity.
If the inputs used to measure the financial assets and liabilities fall within more than one
level described above, the categorization is based on the lowest level input that is significant to
the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized
below:
There were no significant transfers between Level 1 and Level 2 during the second quarter
or first six months of 2011. As of June 30, 2011, Cash and cash equivalents of $12.3 billion
included $11.8 billion of cash equivalents.
Level 3 Valuation Techniques:
Financial assets are considered Level 3 when their fair values are determined using pricing
models, discounted cash flow methodologies or similar techniques and at least one significant model
assumption or input is unobservable. Level 3 financial assets also include certain investment
securities for which there is limited market activity such that the determination of fair value
requires significant judgment or estimation. The Company’s Level
3 investment securities included certain mortgage-backed securities that were valued primarily
using pricing models for which management understands the methodologies. These models incorporate
transaction details such as contractual terms, maturity, timing and amount of future cash inflows,
as well as assumptions about liquidity and credit valuation adjustments of marketplace
participants.
The table below provides a summary of the changes in fair value of all financial assets
measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Financial Instruments not Measured at Fair Value
Some of the Company’s financial instruments are not measured at fair value on a recurring
basis but are recorded at amounts that approximate fair value due to their liquid or short-term
nature, such as cash and cash equivalents, receivables and payables.
The estimated fair value of loans payable and long-term debt (including current portion) at
June 30, 2011 was $18.8 billion compared with a carrying value of $18.3 billion and at December 31,
2010 was $18.7 billion compared with a carrying value of $17.9 billion. Fair value was estimated
using quoted dealer prices.
A summary of gross unrealized gains and losses on available-for-sale investments recorded in
AOCI is as follows:
Available-for-sale debt securities included in Short-term investments totaled $1.6 billion at
June 30, 2011. Of the remaining debt securities, $1.8 billion mature within five years. At June
30, 2011, there were no debt securities pledged as collateral.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with
corporate issuers of securities and financial institutions with which it conducts business. Credit
exposure limits are established to limit a concentration with any single issuer or institution.
Cash and investments are placed in instruments that meet high credit quality standards, as
specified in the Company’s investment policy guidelines. Approximately half of the Company’s cash
and cash equivalents are invested in three highly-rated money market funds.
The majority of the Company’s accounts receivable arise from product sales in the United
States and Europe and are primarily due from drug wholesalers and retailers, hospitals, government
agencies, managed health
care providers and pharmacy benefit managers. The Company monitors the
financial performance and credit worthiness of its customers so that it can properly assess and
respond to changes in their credit profile. The Company also continues to monitor economic
conditions, including the volatility associated with international sovereign economies, and
associated impacts on the financial markets and its business, taking into consideration the global
economic downturn and the sovereign debt issues in certain European countries. The Company
continues to monitor the credit and economic conditions within Greece, Spain, Italy and Portugal,
among other members of the EU. These deteriorating economic conditions, as well as inherent
variability of timing of cash receipts, have resulted in, and may continue to result in, an
increase in the average length of time that it takes to collect accounts receivable outstanding.
The Company does not expect to have write-offs or adjustments to accounts receivable which
would have a material adverse impact on our financial position or results of operations.
In the second quarter of 2011, the Company’s accounts receivable in Greece, Italy, Spain and Portugal totaled
approximately $1.8 billion of which hospital and public sector receivables were
approximately 75%. As of June 30, 2011, the Company’s total accounts receivable outstanding for
more than one year were approximately $370 million, of which approximately 90% related to
accounts receivable in Greece, Italy, Spain and Portugal, mostly comprised of hospital and public
sector receivables.
Derivative financial instruments are executed under International Swaps and Derivatives
Association master agreements. The master agreements with several of the Company’s financial
institution counterparties also include credit support annexes. These annexes contain provisions
that require collateral to be exchanged depending on the value of the derivative assets and
liabilities, the Company’s credit rating, and the credit rating of the counterparty. As of June
30, 2011 and December 31, 2010, the Company had received cash collateral of $114 million and $157
million, respectively, from various counterparties which is recorded in Accrued and other current
liabilities. The Company had not advanced any cash collateral to counterparties as of June 30,
2011 or December 31, 2010.
|
Inventories (Details) (USD $)
|
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Inventories | ||
Finished goods | $ 1,440,000,000 | $ 1,484,000,000 |
Raw materials and work in process | 6,036,000,000 | 5,449,000,000 |
Supplies | 298,000,000 | 315,000,000 |
Total (approximates current cost) | 7,774,000,000 | 7,248,000,000 |
Reduction to LIFO costs | (141,000,000) | (186,000,000) |
Inventories | 7,633,000,000 | 7,062,000,000 |
Recognized as: | ||
Inventories | 6,225,000,000 | 5,868,000,000 |
Other assets | 1,408,000,000 | 1,194,000,000 |
Inventories (Textuals) [Abstract] | ||
Remaining purchase price allocation to inventories | 155,000,000 | 225,000,000 |
Inventories included in Other Assets not expected to be sold within one year, principally vaccines | 1,300,000,000 | 1,000,000,000 |
Inventories included in Other Assets produced in preparation for product launches | $ 111,000,000 | $ 197,000,000 |
Share Based Compensation (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Plans [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amounts of share-based compensation cost recorded in the Consolidated Statement of Income |
The following table provides amounts of share-based compensation cost recorded in the
Consolidated Statement of Income:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumptions for weighted average fair value of options granted |
The weighted average fair value of options
granted for the first six months of 2011 and 2010 was $5.37 and $8.02 per option, respectively, and
was determined using the following assumptions:
|
Financial Instruments (Details 3) (USD $)
In Millions |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Assets | ||
Fair Value | $ 4,011 | $ 3,657 |
Fair Value of Derivative, Asset | 557 | 628 |
Liabilities | ||
Fair Value of Derivative, Liability | 68 | 61 |
Foreign exchange contract [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 0 | 0 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 0 |
Interest rate swap contract [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 0 | 0 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 0 |
Corporate notes and bonds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
U.S. government and agency securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Commercial paper [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Municipal securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Asset-backed securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Mortgage-backed securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Foreign government bonds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Other debt securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Equity securities [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 96 | 117 |
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Investments | 96 | 117 |
Securities held for employee compensation | 197 | 181 |
Purchased currency options | 0 | 0 |
Fair Value of Derivative, Asset | 0 | 0 |
Total assets | 293 | 298 |
Liabilities | ||
Total liabilities | 0 | 0 |
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Written Currency Options [Member]
|
||
Liabilities | ||
Fair Value of Derivative, Liability | 0 | |
Foreign exchange contract [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 106 | 95 |
Liabilities | ||
Fair Value of Derivative, Liability | 62 | 54 |
Interest rate swap contract [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 72 | 56 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 7 |
Corporate notes and bonds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 1,377 | 1,133 |
U.S. government and agency securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 523 | 500 |
Commercial paper [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 1,411 | 1,046 |
Municipal securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 361 |
Asset-backed securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 183 | 171 |
Mortgage-backed securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 134 | 99 |
Foreign government bonds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 56 | 10 |
Other debt securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 3 | 3 |
Equity securities [Member] | Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 31 | 23 |
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Investments | 3,718 | 3,346 |
Securities held for employee compensation | 0 | 0 |
Purchased currency options | 379 | 477 |
Fair Value of Derivative, Asset | 557 | 628 |
Total assets | 4,275 | 3,974 |
Liabilities | ||
Total liabilities | 68 | 61 |
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Written Currency Options [Member]
|
||
Liabilities | ||
Fair Value of Derivative, Liability | 6 | 0 |
Foreign exchange contract [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 0 | 0 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 0 |
Interest rate swap contract [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 0 | 0 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 0 |
Corporate notes and bonds [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
U.S. government and agency securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Commercial paper [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Municipal securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Asset-backed securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Mortgage-backed securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 13 |
Foreign government bonds [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Other debt securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Equity securities [Member] | Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 0 |
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Investments | 0 | 13 |
Securities held for employee compensation | 0 | 0 |
Purchased currency options | 0 | 0 |
Fair Value of Derivative, Asset | 0 | 0 |
Total assets | 0 | 13 |
Liabilities | ||
Total liabilities | 0 | 0 |
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member] | Written Currency Options [Member]
|
||
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 0 |
Foreign exchange contract [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 106 | 95 |
Liabilities | ||
Fair Value of Derivative, Liability | 62 | 54 |
Interest rate swap contract [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value of Derivative, Asset | 72 | 56 |
Liabilities | ||
Fair Value of Derivative, Liability | 0 | 7 |
Corporate notes and bonds [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 1,377 | 1,133 |
U.S. government and agency securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 523 | 500 |
Commercial paper [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 1,411 | 1,046 |
Municipal securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 0 | 361 |
Asset-backed securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 183 | 171 |
Mortgage-backed securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 134 | 112 |
Foreign government bonds [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 56 | 10 |
Other debt securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 3 | 3 |
Equity securities [Member] | Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Fair Value | 127 | 140 |
Fair Value, Measurements, Recurring [Member]
|
||
Assets | ||
Investments | 3,814 | 3,476 |
Securities held for employee compensation | 197 | 181 |
Purchased currency options | 379 | 477 |
Fair Value of Derivative, Asset | 557 | 628 |
Total assets | 4,568 | 4,285 |
Liabilities | ||
Total liabilities | 68 | 61 |
Fair Value, Measurements, Recurring [Member] | Written Currency Options [Member]
|
||
Liabilities | ||
Fair Value of Derivative, Liability | 6 | 0 |
Corporate notes and bonds [Member]
|
||
Assets | ||
Fair Value | 1,377 | 1,133 |
U.S. government and agency securities [Member]
|
||
Assets | ||
Fair Value | 523 | 500 |
Commercial paper [Member]
|
||
Assets | ||
Fair Value | 1,411 | 1,046 |
Municipal securities [Member]
|
||
Assets | ||
Fair Value | 0 | 361 |
Asset-backed securities [Member]
|
||
Assets | ||
Fair Value | 183 | 171 |
Mortgage-backed securities [Member]
|
||
Assets | ||
Fair Value | 134 | 112 |
Foreign government bonds [Member]
|
||
Assets | ||
Fair Value | 56 | 10 |
Other debt securities [Member]
|
||
Assets | ||
Fair Value | 3 | 3 |
Equity securities [Member]
|
||
Assets | ||
Fair Value | $ 324 | $ 321 |
Other (Income) Expense, Net (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (Income) Expense, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (income) expense, net |
Other (income) expense, net, consisted of:
|
Other (Income) Expense, Net
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (Income) Expense, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (Income) Expense, Net |
13. Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Other, net (as presented in the table above) for the first six months of 2011 reflects a $500
million charge related to the resolution of the arbitration proceeding involving the Company’s
rights to market Remicade and Simponi (see Note 9 to the interim consolidated financial
statements), as well as a $127 million gain on the sale of certain manufacturing facilities and
related assets. Other, net for the second quarter and first six months of 2010 reflects $443
million of income recognized upon AstraZeneca’s asset option exercise. Other, net for the first
six months of 2010 also reflects $102 million of income recognized on the settlement of certain
disputed royalties.
Exchange losses for the first six months of 2011 declined as compared with the first six months of
2010 primarily driven by a Venezuelan currency devaluation in the first quarter of 2010 resulting
in the recognition of $80 million of exchange losses. Effective January 11, 2010, the Venezuelan
government devalued its currency from at BsF 2.15 per U.S. dollar to a two-tiered official exchange
rate at (1) “the essentials rate” at BsF 2.60 per U.S. dollar and (2) “the non-essentials rate” at
BsF 4.30 per U.S. dollar. In January 2010, the Company was required to remeasure its local
currency operations in Venezuela to U.S. dollars as the Venezuelan economy was determined to be
hyperinflationary. Throughout 2010, the Company settled its transactions at the essentials rate
and therefore remeasured monetary assets and liabilities using the essentials rate. In December
2010, the Venezuelan government announced it would eliminate the
essentials rate and, effective
January 1, 2011, all transactions would be settled at the official rate of at BsF 4.30 per U.S.
dollar. As a result of this announcement, the Company remeasured its December 31, 2010 monetary
assets and liabilities at the new official rate. Interest paid for the six months ended June 30,
2011 and 2010 was $194 million and $312 million, respectively, which excludes commitment fees. Interest
paid for the six months ended June 30, 2011 is net of $175 million received by the Company
from the termination of certain interest rate swap contracts during the period (see Note 5).
|
Segment Reporting (Details) (USD $)
In Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Revenues and profits for segments | ||||
Segment revenues | $ 12,025 | $ 11,163 | $ 23,454 | $ 22,398 |
Profits | 1,672 | 1,241 | 3,401 | 1,856 |
Reportable Segments [Member]
|
||||
Revenues and profits for segments | ||||
Profits | 7,098 | 6,614 | 14,030 | 13,074 |
Pharmaceutical segment [Member]
|
||||
Revenues and profits for segments | ||||
Segment revenues | 10,360 | 9,638 | 20,179 | 19,303 |
Profits | 6,443 | 5,987 | 12,659 | 11,727 |
All Other Segment [Member]
|
||||
Revenues and profits for segments | ||||
Segment revenues | 1,665 | 1,525 | 3,275 | 3,095 |
Profits | $ 655 | $ 627 | $ 1,371 | $ 1,347 |
Inventories
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
6. Inventories
Inventories consisted of:
As of June 30, 2011 and December 31, 2010, $155 million and $225 million, respectively, of
purchase accounting adjustments to inventories remained which are recognized as a component of
Materials and production costs as the related inventories are sold. Amounts recognized as Other
assets are comprised almost entirely of raw materials and work in process inventories. At June 30,
2011 and at December 31, 2010, these amounts included $1.3 billion and $1.0 billion, respectively,
of inventories not expected to be sold within one year, principally vaccines. In addition, these
amounts included $111 million and $197 million at June 30, 2011 and December 31, 2010,
respectively, of inventories produced in preparation for product launches.
|
Segment Reporting
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting |
16. Segment Reporting
The Company’s operations are principally managed on a products basis and are comprised of four
operating segments — Pharmaceutical, Animal Health, Consumer Care and Alliances (which includes
revenue and equity income from the Company’s relationship with AZLP). The Animal Health, Consumer
Care and Alliances segments are not material for separate reporting and are included in all other
in the table below. The Pharmaceutical segment includes human health pharmaceutical and vaccine
products marketed either directly by the Company or through joint ventures. Human health
pharmaceutical products consist of therapeutic and preventive agents, generally sold by
prescription, for the treatment of human disorders. The Company sells these human health
pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies
and managed health care providers such as health maintenance organizations, pharmacy benefit
managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and
adult vaccines, primarily administered at physician offices. The Company sells these human health
vaccines primarily to physicians, wholesalers, physician distributors and government entities. A
large component of pediatric and adolescent vaccines is sold to the U.S. Centers for Disease
Control and Prevention Vaccines for Children program, which is funded by the U.S. government.
Additionally, the Company sells vaccines to the Federal government for placement into vaccine
stockpiles. The Company also has animal health operations that discover, develop, manufacture and
market animal health products, including vaccines, which the Company sells to veterinarians,
distributors and animal producers. Additionally, the Company has consumer care operations that
develop, manufacture and market over-the-counter, foot care and sun care products, which are sold
through wholesale and retail drug, food chain and mass merchandiser outlets. Segment composition
reflects certain managerial changes that have been implemented. Consumer Care product sales
outside the United States and Canada, previously included in the Pharmaceutical segment, are now
included in the Consumer Care segment. Segment disclosures for prior periods have been recast on a
comparable basis with 2011.
Revenues and profits for these segments are as follows:
Segment profits are comprised of segment revenues less certain elements of materials and
production costs and operating expenses, including components of equity income or loss from
affiliates and depreciation and amortization expenses. For internal management reporting presented
to the chief operating decision maker, Merck does not allocate production costs, other than
standard costs, research and development expenses or general and administrative expenses, nor the
cost of financing these activities. Separate divisions maintain responsibility for monitoring and
managing these costs, including depreciation related to fixed assets utilized by these divisions
and, therefore, they are not included in segment profits.
Sales of the Company’s products were as follows:
A reconciliation of segment profits to Income before taxes is as follows:
Other profits are primarily comprised of miscellaneous corporate profits, as
well as operating profits related to third-party manufacturing sales, divested products or
businesses and other supply sales. Adjustments represent the elimination of the effect of double
counting certain items of income and expense. Equity income from affiliates includes taxes paid at
the joint venture level and a portion of equity income that is not reported in segment profits.
Other expenses, net include expenses from corporate and manufacturing cost centers and other
miscellaneous income (expense), net.
|
Pension and Other Postretirement Benefit Plans (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Other Postretirement Benefit Plans [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of net cost of defined benefit pension plans |
The Company has defined benefit pension plans covering eligible employees in the United States
and in certain of its international subsidiaries. The net cost of such plans consisted of the
following components:
The Company provides medical, dental and life insurance benefits, principally to its eligible
U.S. retirees and similar benefits to their dependents, through its other postretirement benefit
plans. The net cost of such plans consisted of the following components:
|
Basis of Presentation (Policies)
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Basis of presentation [Abstract] | |
Recently Adopted Accounting Standards |
Recently Adopted Accounting Standards
In October 2009, the Financial Accounting Standards Board (“FASB”) issued new guidance for
revenue recognition with multiple deliverables. The Company adopted this guidance prospectively
for revenue arrangements entered into or materially modified on or after January 1, 2011. This
guidance eliminates the residual method under the current guidance and replaces it with the
“relative selling price” method when allocating revenue in a multiple deliverable arrangement. The
selling price for each deliverable shall be determined using vendor specific objective evidence of
selling price, if it exists, otherwise third-party evidence of selling price shall be used. If
neither exists for a deliverable, the vendor shall use its best estimate of the selling price for
that deliverable. The effect of adoption on the Company’s financial position and results of
operations was not material.
|
Contingencies and Legal Defense Costs |
Legal defense costs expected to be incurred in connection with a loss contingency are accrued
when probable and reasonably estimable.
|
Joint Ventures and Other Equity Method Affiliates (Details) (USD $)
In Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Equity income from affiliates | ||||
Equity income from affiliates | $ 55 | $ 43 | $ 193 | $ 180 |
AstraZeneca LP [Member]
|
||||
Equity income from affiliates | ||||
Equity income from affiliates | 44 | 40 | 177 | 165 |
Other [Member]
|
||||
Equity income from affiliates | ||||
Equity income from affiliates | $ 11 | $ 3 | $ 16 | $ 15 |
Financial Instruments (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of derivatives segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments |
Presented in the table below is the fair value of derivatives segregated between those
derivatives that are designated as hedging instruments and those that are not designated as hedging
instruments:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Location and pretax gain or loss amounts for derivatives that are: (i) designated in a fair value hedging relationship, (ii) designated in a cash flow hedging relationship, (iii) designated in a foreign currency hedging relationship (net investment hedge) and (iv) not designated in a hedging relationship |
The table below provides information on the location and pretax gain or loss amounts for
derivatives that are: (i) designated in a fair value hedging relationship, (ii) designated in a
cash flow hedging relationship, (iii) designated in a foreign currency hedging relationship (net
investment hedge) and (iv) not designated in a hedging relationship:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial assets and liabilities measured at fair value on a recurring basis |
Financial assets and liabilities measured at fair value on a recurring basis are summarized
below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in fair value, including net transfers in and/or out, of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) |
The table below provides a summary of the changes in fair value of all financial assets
measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gross unrealized gains and losses on the Company's available-for-sale investments, including those pledged as collateral, recorded in Accumulated Other Comprehensive Income ("AOCI") |
A summary of gross unrealized gains and losses on available-for-sale investments recorded in
AOCI is as follows:
|
Restructuring
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring |
2. Restructuring
Merger Restructuring Program
In February 2010, the Company commenced actions under a global restructuring program (the
“Merger Restructuring Program”) in conjunction with the integration of the legacy Merck and legacy
Schering-Plough businesses. This Merger Restructuring Program is intended to optimize the cost
structure of the combined company. Additional actions under the program continued during 2010. On
July 29, 2011, the Company announced the next phase of the Merger Restructuring Program during
which the Company expects to reduce its workforce measured at the time of the Merger by an
additional 12% to 13% across the Company worldwide. A majority of the workforce
reductions in this phase of the Merger Restructuring Program relate to manufacturing,
including Animal Health, administrative and headquarters organizations. Previously announced
workforce reductions of approximately 17% in earlier phases of the program primarily reflect the
elimination of positions in sales, administrative and headquarters organizations, as well as from
the sale or closure of certain manufacturing and research and development sites and the
consolidation of office facilities. The Company will continue to hire employees in strategic growth areas of the business as necessary. The Company will continue to
pursue productivity efficiencies and evaluate its manufacturing supply chain capabilities on an
ongoing basis which may result in future restructuring actions.
The Company recorded total pretax restructuring costs of $808 million and $830 million in the
second quarter of 2011 and 2010, respectively, and $921 million and $1.1 billion for the first six
months of 2011 and 2010, respectively, related to this program. Since inception of the Merger
Restructuring Program through June 30, 2011, Merck has recorded total pretax accumulated costs of
approximately $4.2 billion and eliminated approximately 12,900 positions comprised of employee
separations, as well as the elimination of contractors and over 2,500
positions that were vacant at the time of the Merger. The restructuring actions
under the Merger Restructuring Program are expected to be substantially completed by the end of
2013, with the exception of certain actions, principally manufacturing-related, which are expected to be completed by
2015, with the total cumulative pretax costs estimated to be approximately $5.8 billion to $6.6
billion. The Company estimates that approximately two-thirds of the cumulative pretax costs relate
to cash outlays, primarily related to employee separation expense. Approximately one-third of the
cumulative pretax costs are non-cash, relating primarily to the accelerated depreciation of
facilities to be closed or divested.
2008 Global Restructuring Program
In October 2008, Old Merck announced a global restructuring program (the “2008 Restructuring
Program”) to reduce its cost structure, increase efficiency, and enhance competitiveness. As part
of the 2008 Restructuring Program, the Company expects to eliminate approximately 7,200 positions
— 6,800 active employees and 400 vacancies — across the Company worldwide by the end of 2011.
Pretax restructuring costs of $1 million and $66 million were recorded in the second quarter of
2011 and 2010, respectively, and $5 million and $131 million in the first six months of 2011 and
2010, respectively, related to the 2008 Restructuring Program. Since inception of the 2008
Restructuring Program through June 30, 2011, Merck has recorded total pretax accumulated costs of
$1.6 billion and eliminated approximately 5,980 positions comprised of employee separations and the
elimination of contractors and vacant positions. The 2008 Restructuring Program is expected to be
completed by the end of 2011, except for certain manufacturing-related
actions, with the total cumulative pretax costs estimated to be up to $2.0 billion. The Company estimates that two-thirds of the cumulative pretax costs relate to cash
outlays, primarily from employee separation expense. Approximately one-third of the cumulative
pretax costs are non-cash, relating primarily to the accelerated depreciation of facilities to be
closed or divested.
For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to Merger Restructuring Program and 2008
Restructuring Program activities by type of cost:
Separation costs are associated with actual headcount reductions, as well as those
headcount reductions which were probable and could be reasonably estimated. In the first six
months of 2011, separation costs for the Merger Restructuring Program include a reduction of
separation reserves of approximately $50 million resulting from the Company’s decision in the first
quarter to retain approximately 380 employees at its Oss, Netherlands research facility that had
previously been expected to be separated. In the second quarter of 2011 and 2010, approximately
585 positions and 2,435 positions, respectively, were eliminated under the Merger Restructuring
Program and approximately 60 positions and 240 positions, respectively, were eliminated under the
2008 Restructuring Program. In the first six months of 2011 and 2010,
approximately 1,335
positions and 7,585 positions, respectively, were eliminated under the Merger Restructuring Program
and approximately 180 positions and 775 positions, respectively, were eliminated under the 2008
Restructuring Program. These position eliminations were comprised of actual headcount reductions
and the elimination of contractors and vacant positions.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative
facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation
costs represent the difference between the depreciation expense to be recognized over the revised
useful life of the site, based upon the anticipated date the site will be closed or divested, and
depreciation expense as determined utilizing the useful life prior to the restructuring actions.
All of the sites have and will continue to operate up through the respective closure dates, and
since future cash flows were sufficient to recover the respective book values, Merck was required
to accelerate depreciation of the site assets rather than write them off immediately.
Other
activity in the second quarter of 2011 and 2010 includes asset abandonment, shut-down and
other related costs. Additionally, other activity includes employee-related costs such as
curtailment, settlement and termination charges associated with pension and other postretirement
benefit plans (see Note 12) and share-based compensation costs.
The following table summarizes the charges and spending relating to Merger Restructuring
Program and 2008 Restructuring Program activities for the six months ended June 30, 2011:
Legacy Schering-Plough Program
Prior to the Merger, Schering-Plough commenced a Productivity Transformation Program which was
designed to reduce and avoid costs and increase productivity. The Company recorded accelerated
depreciation costs included in Materials and production of $7 million and $6 million for the second
quarter of 2011 and 2010, respectively, and $16 million and $9 million for the first six months of
2011 and 2010, respectively. In addition, the second quarter and first six months of 2010 includes
a net gain of $8 million reflected in Restructuring costs
primarily related to the sale of a manufacturing
facility. The remaining reserve associated with this program was $38 million at June 30, 2011.
|
Share-Based Compensation Plans
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Plans [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Plans |
11. Share-Based Compensation Plans
The Company has share-based compensation plans under which employees and non-employee
directors may be granted restricted stock units (“RSUs”). In addition, the Company grants options
to purchase shares of Company common stock at the fair market value at the time of grant and
performance share units (“PSUs”) to certain management-level employees. The Company recognizes the
fair value of share-based compensation in net income on a straight-line basis over the requisite
service period.
The following table provides amounts of share-based compensation cost recorded in the
Consolidated Statement of Income:
During the first six months of 2011 and 2010, the Company granted 8 million RSUs with a
weighted-average grant date fair value of $36.47 per RSU and 10 million RSUs with a
weighted-average grant date fair value of $33.89 per RSU, respectively.
During the first six months of 2011 and 2010, the Company granted 8 million options with a
weighted-average exercise price of $36.55 per option and 7 million options with a weighted-average
exercise price of $34.25 per option, respectively.
The weighted average fair value of options
granted for the first six months of 2011 and 2010 was $5.37 and $8.02 per option, respectively, and
was determined using the following assumptions:
At
June 30, 2011, there was $565 million of total pretax unrecognized compensation expense
related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted
average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated
expenses.
|
Segment Reporting (Details Textuals) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Segment Reporting (Textuals) [Abstract] | ||||
Number of operating segments | 4 | |||
AstraZeneca LP [Member]
|
||||
Schedule of Equity Method Investments [Line Items] | ||||
Revenue from AstraZeneca LP | $ 306 | $ 241 | $ 628 | $ 605 |
Earnings per Share
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share |
15. Earnings Per Share
The Company calculates earnings per share pursuant to the two-class method, which is an
earnings allocation formula that determines earnings per share for common stock and participating
securities according to dividends declared and participation rights in undistributed earnings.
Under this method, all earnings (distributed and undistributed) are allocated to common shares and
participating securities based on their respective rights to receive dividends. RSUs and certain
PSUs granted before December 31, 2009 to certain management level employees participate in
dividends on the same basis as common shares and such dividends are nonforfeitable by the holder.
As a result, these RSUs and PSUs meet the definition of a participating security. For RSUs and
PSUs issued on or after January 1, 2010, dividends declared during the vesting period are payable
to the employees only upon vesting and therefore such RSUs and PSUs do not meet the definition of a
participating security.
The calculations of earnings per share under the two-class method are as follows:
For the three months ended June 30, 2011 and 2010, 138 million and 195 million,
respectively, and for the six months ended 2011 and 2010, 173 million and 179 million, respectively,
of common shares issuable under share-based compensation plans were excluded from the computation
of earnings per common share assuming dilution because the effect would have been antidilutive.
|
Acquisitions, Divestitures, Research Collaborations and License Agreements (Details) (USD $)
In Millions, except Per Share data |
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Acquisitions, Divestitures, Research Collaborations and License Agreements (Textuals) [Abstract] | |
Tender offer price per share in cash | $ 5.00 |
Total amount of cash paid for acquisition | $ 420 |
Gain on sale of manufacturing facilities and related assets | $ 127 |